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 Interleukin-2 (IL-2) induces neuropsychiatric toxicity in patients, which is often 
dose-limiting and currently not well understood due to lack of suitable experimental 
methods. We therefore evaluated a number of experimental techniques to quantify 
changes in the brain vasculatures in a well-characterized IL-2 treatment murine model.  
Direct measurement of small molecule accumulation, wet versus dry brain weight 
comparison, and proton density MRI lacked sensitivity and reliability to detect small 
changes in the brain water content. Successful methods included dynamic contrast 
enhanced (DCE) MRI and immunohistochemistry using specific endothelial markers to 
identify vasodilation in carefully matched regions of the mouse brain. Both methods 
demonstrated significant vasodilation of the brain blood vessels following IL-2 treatment. 
DCE MRI further indicated that IL-2 increased brain blood vessel permeability to the 
contrast agent. Using these techniques, we evaluated the mechanism involved in IL-2-
induced neuropsychiatric toxicity. We initially established that mice exhibited behavioral 
changes following IL-2 treatment, indicating that IL-2 affected the brain in the murine 
model as in patients. The spontaneous movement, rearing, and grooming significantly 
decreased by day 2 following IL-2 treatment in the C3H/HeN mice, while the motor 
strength and coordination of these mice were affected by day 4. Vasodilation and 
microvascular permeability evaluated by immunohistochemistry and DCE MRI were not 
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observed until day 4, suggesting that IL-2-induced behavioral changes occurred before 
detectable vasodilation and microvascular permeability. Further experiments established 
that IL-2 mediates its cardiovascular toxicity via its receptor on leukocytes, instead of a 
direct action on endothelial cells. This finding supports the concept that the dose-limiting 
toxicities associated with IL-2 therapy are mediated by the secondary inflammatory 
cytokine storm. We therefore evaluated the role of nitric oxide (NO) produced by 
endothelial NO synthase (eNOS) in vascular changes in the brain following IL-2 
treatment. The data indicated that activation of eNOS-mediated changes in vascular 
permeability and vasodilation correlate with motor function changes induced by IL-2, 
while changes in spontaneous behavior following IL-2 treatment are not mediated by NO. 
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Interleukin-2 (IL-2) was first identified in 1976 as the active component of a 
lymphocyte conditioned medium that supported the long-term growth of T lymphocytes 
in vitro (1) and hence named T-cell growth factor (TCGF). In 1981, it was characterized 
as a variably glycosylated 15,500 Dalton protein (2). IL-2 was then purified to 
homogeneity (3) and its cDNA was cloned in 1983 (4). The gene that expresses IL-2 
spans four exons and is located on chromosome 4q26–q27 in human or chromosome 3 in 
mouse (5). The human cDNA encodes a polypeptide composed of 153 amino acids, with 
the first 20 amino acids serving as a signal sequence and are cleaved prior to secretion. 
The murine amino acid sequence is about 60% homology to the human sequence. Both 
are secreted as single polypeptides with molecular weights of 15–17 kDa (6). The size 
and charge variability of IL-2 depends on the degrees of glycosylation, which have no 
effect on activity (6). Therefore, recombinant IL-2 is equally effective in stimulating T-
cells proliferation as glycosylated IL-2. Recombinant human IL-2 has been found to be 
effective in mice. 
 The crystal structure of IL-2 was determined in 1991 (7), which showed that IL-2 
folds into four α (alpha) helical domains (named A, B, C, and D) connected by 3 loops 
(A–B, B–C, and C–D loops) and has a single disulfide bridge (Fig. 1.1). The first and last 
two α helices are each connected by a long crossover loop, resulting in an “up-up-down-
down” topological structure because the first two α helices (the A and B helices) appear 
to orient in an upward direction while the last two α helices (C and D) can be oriented in 
a downward direction as viewed from the NH2- to COOH-terminal. IL-2 also has two 





























 In the immune system, a small amount of IL-2 is mainly secreted by antigen-
activated T-helper (Th1) lymphocytes. Additionally, dendritic cells, monocytes, natural 
killer (NK) cells, and activated CD8+ T-cells can also produce IL-2. In the normal brain, 
IL-2 expression is extremely low and regionally restricted. IL-2 in the brain is produced 




 IL-2 was the first cytokine identified to mediate its effects via a cell surface 
receptor that has similar characteristics to those of classic hormone receptors, including 
stereospecificity, saturability, and high affinity (8). IL-2 binds to a well-characterized 
heterotrimeric receptor on its target cells (9). The IL-2 receptor (IL-2R) is composed of 
three noncovalently linked distinct chains: 1) the alpha chain (IL-2Rα, CD25), 2) beta 
chain (IL-2Rβ, CD122), and 3) a common cytokine receptor gamma chain (γc, CD132) 
(10-18). IL-2Rα is essential for specific binding of IL-2. By itself, IL-2Rα binds to IL-2 
with a low affinity (binding affinity Kd ≈ 10 nM) and does not play a role in signal 
transduction (19). IL-2Rβ alone also has a very low affinity (Kd ≈ 100 nM) whereas 
isolated γc has no detectable binding affinity to IL-2, but the complex of IL-2Rβ and γc 
binds to IL-2 with an intermediate affinity (Kd ≈ 1 nM) (20). This two-part receptor 
complex is found on macrophages, NK cells, and resting T cells (9). Upon IL-2 binding, 
IL-2Rβ and γc complex is sufficient and necessary for effective signal transduction via 
the heterodimerization of their cytoplasmic domains (21-22). A complex of all three IL-
2R subunits (IL-2Rα, IL-2Rβ, and the γc) binds to IL-2 with high affinity (Kd ≈ 10 pM) 
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and is the receptor form found on activated T cells (18) that mediates most biological 
activities of IL-2 in vivo (9). There is homology between the mouse IL-2R and human IL-
2R. In the mouse brain, IL-2 receptors have been found on microglial cells and on myelin 
(23-24), mainly in the hippocampus, frontal cortex, and striatum regions (25). 
 The recently elucidated structure of the IL-2 and IL-2R quaternary complex 
revealed many details of the interactions between IL-2 and its various receptor 
complexes. The structure of IL-2Rα and its mode of interaction with IL-2 differ from the 
typical cytokine receptor (26). IL-2Rα folds into two “sushi-like” domains, which form 
five-stranded β-sheet sandwiches (27). A long connecting peptide of the IL-2Rα, 
between its globular head and the transmembrane segment, allows its binding domain to 
extend away from the cell surface and reach the dorsally located binding site on IL-2 
(28), capturing the IL-2 molecule and setting it against the βγ complex. IL-2Rβ and γc, 
on the other hand, contain a “WSXWS” motif in the C-terminal domain and two disulfide 
bonds in the N-terminal domain that are characteristics of the class I cytokine receptor 
superfamily (29). They consist of N- and C-terminal fibronectin-III domains, which are 
characterized by a β-sandwich sheet containing seven antiparallel strands arranged in a 
three-on-four topology, and their bases converge to form a Y shape where IL-2 binds to 
(28). The formation of the IL-2 and IL-2R quaternary complex is mediated by four 
binding sites: IL-2/IL-2Rα, IL-2/IL-2Rβ, IL-2/γc, and IL-2Rβ/γc (28). IL-2/IL-2Rα 
interface is the largest of the three interfaces with a hydrophobic center, a polar periphery 
featuring five ion pairs, and seven hydrogen bonds between IL-2 and IL-2Rα (27). 
Interestingly, IL-2Rα does not associate with IL-2Rβ or γc and the three contact sites on 
IL-2 normally do not overlap with each other, except for a small region of helix A that 
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wedges tightly between IL-2Rβ and γc to form a three-way junction for a composite 
binding site for the final γc recruitment (27). There are only minor conformational 
changes observed in the IL-2 structure upon forming a quaternary complex with IL-2R, 
the most significant is the arrangement of the BC loop due to crystal-packing interactions 
(27). 
Whereas IL-2Rα chain (CD25) is specific to the IL-2 receptor, IL-2Rβ is also a 
subunit of the IL-15 receptor while the γc is shared by IL-4, IL-7, IL-9, IL-15, and IL-21 
receptors (30). Hence the redundancy of IL-2 functions with those of other cytokines 
sharing a common γc in their receptors. IL-2 exerts its diverse activities by binding to 
different receptor complexes of IL-2R depending on which components of the receptor 
are expressed on the cell surface. A crucial number of IL-2 receptors must be activated 
before a single T cell will make the irreversible, all-or-none commitment to pass through 
the G1 restriction point to undergo proliferation (31-32). A number of other cells 
(i.e.,monocytes, fibroblasts, keratinocytes, and perhaps endothelial cells) express IL-2Rβ 
and γc on their cell surface, but it is not clear whether IL-2 binds to these receptors and 
plays a physiological role in these cells.  
 
Signaling Pathways and Biological Activities of IL-2 
IL-2 binding to IL-2R activates numerous intracellular tyrosine kinases, leading to 
a rapid increase in tyrosine phosphorylation of many cellular proteins and subsequent 
increase in expression of several nuclear proto-oncogenes critical for proliferation (33). 
The cytoplasmic domains of IL-2Rβ and γc associate with Janus kinases JAK1 and 
JAK3, respectively (34-35). IL-2 binding to IL-2R activates these Janus kinases, leading 
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to phosphorylation and concurrent induction of STAT (signal transducers and activators 
of transcription) proteins (36). Although several STAT-like DNA binding activities seem 
to be involved in the IL-2 signaling pathway (37-38), activation of STAT5 protein in 
particular has been functionally linked to the IL-2Rβ subunit via a redundant tyrosine-
containing motif found in several cytokine receptors (39-41). Upon phosphorylation, 
STAT5 proteins dissociate from the IL-2Rβ, dimerize, and translocate to the nucleus 
where they promote the transcription of IL-2 specific genes. Additionally, IL-2 binding to 
IL-2R also triggers other signaling pathways, such as phosphorylation of the Src-family 
protein tyrosine kinases Lck (leukocyte-specific protein tyrosine kinase) and Syk (spleen 
tyrosine kinase), expression of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2), 
stimulation of the phosphatidylinositol-3-kinase–AKT pathway, and stimulation of the 
Ras–Raf-mitogen-activated-protein-kinase pathway, leading to the activation of Fos- and 
Jun-containing transcription factor complexes (42). 
 IL-2 plays a key role in cell-mediated immunity (43). At low concentrations (10-
100 IU/ml), IL-2 is a potent autocrine T-cell growth factor and is the key cytokine 
responsible for rapid activation, clonal expansion, and differentiation of antigen-activated 
T-cells (44). It also plays a role in the proliferation and survival of mature B-cells, and in 
enhancing the phagocytic capability, oxidative burst, and microbicidal activities of 
monocytes (i.e., macrophages and neutrophils). Moreover, IL-2 promotes the 
proliferation of NK cells and activates their cytotoxic function. High concentrations of 
IL-2 (> 600 IU/ml) rapidly activate a population of NK cell-derived cytotoxic 
lymphocytes named lymphokine-activated killer (LAK) cells (45). These cells are termed 
“nonspecific” killer cells because their cytotoxicity does not require antigen presentation 
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in the context of self-MHC on target cells (46). Thus LAK cells demonstrate killing 
against almost all cultured and freshly isolated malignant cells (47-48), including 
multidrug-resistant cancer cells (49). Activation of lymphocytes by IL-2 also strongly 
induces production of inflammatory cytokines. These secondarily released cytokines 
include IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12, IL-13, tumor necrosis factor 
(TNF), interferon (IFN)-γ, lymphotoxin (LT), and granulocyte-macrophage colony-
stimulating factor (GM-CSF) (44). Lastly, both IL-2 and IL-2R knockout mice have been 
found to suffer from lymphoproliferation followed by lethal autoimmunity, indicating 
that IL-2 also has a crucial role in the termination of T-cell responses and maintenance of 
self-tolerance (50). IL-2 regulates the T-cell tolerance via a group of cells called T 
regulatory cells (Treg) and this function is the only known nonredundant activity of IL-2. 
 
Preclinical Studies and Clinical Uses of IL-2 
 Activation of cytolytic T-cells and LAK cells cytotoxicity against tumor cells in 
vitro by IL-2 led to the evaluation of this cytokine as an anti-cancer drug. In preclinical 
studies, concurrent administrations of IL-2 and LAK cells on tumor-bearing mice resulted 
in the regressions of liver and lung metastases (51-52). These tumor regressions were 
associated with prolonged survival of the experimental mice (53-54), and correlated with 
both increasing doses of LAK cells (up to 108 cells/mouse) and IL-2 (up to 105 IU every 
8 hours) (51, 55-56). Higher doses of IL-2 were lethal to experimental mice due to the 
development of cardiovascular toxicities. 
 In clinical studies, cancer therapy using a high-dose i.v bolus of IL-2 induced 10-
15% partial and 5-7% complete responses in patients with metastatic renal cell carcinoma 
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and malignant melanoma (57-58). About 60% of the complete responses proved durable 
with up to 20 years of follow-up (59). IL-2 therapy was consequently approved by the 
FDA for treatment of metastatic renal cell carcinoma and melanoma in 1992 and 1998, 
respectively. To date, IL-2 remains the only clinically available agent that can induce 
durable complete remissions of metastatic melanoma and renal cell carcinoma in patients 
despite the dramatic increase in treatment options in the past 4 years. Other agents, such 
as V600E B-raf specific inhibitor for treatment of melanoma (60) or inhibitors of mTOR 
(mammalian target of rapamycin) and VEGF (vascular endothelial growth factor) 
pathways for treatment of renal cancer (61), predominantly induce tumor growth arrest, 
requiring ongoing administration of these expensive drugs to maintain clinical responses. 
Attempts to improve IL-2 based immunotherapy include concomitant adoptive transfer of 
in vitro activated LAK cells (62-64) or tumor specific CD8+ T-cells (termed tumor 
infiltrating lymphocytes or TILs) or vaccines directed against the cancer cells. These 
modifications were performed to enhance the immune activities towards the tumor, but 
have not been proven superior to the treatment with IL-2 alone (57, 65). 
 
Dose-limiting Cardiovascular Toxicities of IL-2 Therapy 
 The effectiveness as well as a broader utilization of IL-2 therapy as a cancer 
treatment is limited by its severe dose-limiting toxicities, which include cardiovascular 
and neuropsychiatric toxicities (64, 66-67). The two most prominent cardiovascular 
toxicities of IL-2 administration are vascular leak syndrome (VLS) and hypotension. IL-2 
induced VLS is characterized by generalized extravasations of intravascular fluid into 
interstitial tissues. It is associated with marked fluid retention (weight gain), noncardiac 
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pulmonary edema, and reversible renal dysfunction (68). In conjunction with VLS and 
intravascular volume depletion, IL-2 also induces hypotension, due to a marked decrease 
in systemic vascular resistance and hypoperfusion of vital organs, such as the heart and 
kidneys (69). 
 These IL-2 induced cardiovascular toxicities are thought to be indirectly mediated 
by the inflammatory cytokines released upon IL-2 administration, termed a “cytokine 
storm” (70). These secondarily released cytokines, particularly IL-5, IL-6, IFNγ, GM-
CSF, and TNFα (71-74), reach high levels in patient serum. High dose of steroids can 
block IL-2 induced cardiovascular toxicity, but also completely abrogate therapeutic 
responses, indicating that these secondarily released cytokines may also contribute to the 
IL-2 treatment response (75). These secondary inflammatory cytokines, mainly IFNγ and 
TNF, can induce the production of nitric oxide (NO) through activation of the inducible 
L-arginine:NO synthesis pathway (76-80). The levels of nitrate (metabolites of NO) in 
the serum and urine of patients have been shown to be elevated 6–10-fold on days 5–7 
after a 5-day treatment course of IL-2 (81). Studies in our lab have shown that the 
mechanism of IL-2 induced VLS is via induction of NO synthesis by endothelial NO 
synthase (82) whereas the hypotension appears to be due to catecholamine oxidation by 
superoxide and/or peroxynitrite (83). 
 
Nitric Oxide 
In 1980, a small molecule released by the endothelial cells that diffuses to and 
relaxes the adjacent muscle was identified (84) and named endothelial derived relaxing 
factor (EDRF). This vasodilator was later demonstrated to be NO (85-87). There are 
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various stimuli that can act on the endothelial cells to cause relaxation of vascular smooth 
muscle and therefore vasodilation. A few stimuli, such as adenosine, histamine (via H2 
receptors), and atrial natriuretic peptide, cause vasodilation independent of the 
endothelium whereas acetylcholine, substance P, vasoactive intestinal peptide, histamine, 
bradykinin, and some other vasodilators act via endothelium by causing the release of NO 
(88). Many additional endothelium-derived vasodilator and vasoconstrictor players have 
also been identified (i.e., prostaglandin H2, endothelin-1, and the endothelium-derived 
hyperpolarizing factor), but none of these molecules play such a crucial role in the 
regulation of vascular tone and homeostasis as NO. The fluid shear stress (shear stretch) 
exerted on the endothelium by the flowing blood is the main stimulus for a continuous 
synthesis of NO in vivo (89-90). Changes in shear stress are detected by the stretch 
receptors on endothelial cells, which are connected to the endothelial cytoskeleton by cell 
membrane adaptor proteins (i.e., integrins). Activation of the endothelial cytoskeleton 
results in the release of NO from endothelial cells that diffuses to the vascular smooth 
muscle cells and induces vasodilation and increased blood flow. 
Nitric oxide, with a chemical formula of NO, is a small gas molecule under 
ambient conditions. It is extremely labile, with a half-life of only about 3–5 seconds, after 
which it is oxidized into nitrites and nitrates by water or oxygen (91). NO is also highly 
lipophilic and readily diffusible, and therefore can diffuse and traverse multiple cell 
membranes to reach its numerous targets, making it an ideal signaling messenger. The 
known repertoire of NO functions in physiologic and pathological processes has steadily 
increased in recent years along with a better understanding of its diverse biochemical 
targets (91-92). NO interacts with various types of protein bound metal centers and has a 
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susceptibility to interact with cysteine thiol groups and other nucleophilic amino acids, 
such as tyrosine residues in a process called nitrosation. It also has several molecular 
targets, which upon interaction can modulate gene expression, mRNA stability and 
translation, as well as intracellular signaling (93). 
NO relaxes smooth muscle by stimulating the synthesis of cGMP (cyclic 
guanosine monophosphate) (94). It augments cGMP levels by interacting with the heme-
containing soluble guanylate cyclase (sGC) (95-96), displacing the iron from the plane of 
the heme molecule (97). This interaction leads to sGC structural change and activation, 
resulting in increased intracellular cGMP production (98). Subsequent events include the 
activation of calcium activated potassium channels (99), activation of cGMP-dependent 
protein kinases (100), and decreases in cytosolic calcium (Ca2+) concentration in cardiac 
and endothelial smooth muscle cells via alterations in calcium transporter function (101-
103). The final result of these events is decreased phosphorylation of myosin light chain, 
resulting in smooth muscle relaxation (104). 
The mechanism of action of most pharmacologically useful vasodilators involves 
either direct release of NO or indirect metabolism of nitrates to NO (105). Nitroglycerin 
and the organic nitrates, which are potent treatments of cardiac angina, act by stimulating 
guanylate cyclase after they are converted to NO, resulting in blood vessel relaxation 
(106-107). In contrast, when various derivatives of arginine that inhibit NO synthase are 
administered to humans (108-109) or experimental animals (110-112), they result in a 
rapid rise in blood pressure, suggesting that NO plays a direct role in the regulation of 
blood pressure. NO is also involved in vascular remodeling and angiogenesis, and has 
been implicated in atherosclerosis, a pathological damage of endothelium resulting in 
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stroke. NO can inhibit blood clotting by preventing platelet aggregation (113-115) and 
adhesion (116-117). Moreover, NO is thought to play a key role in diffusion across 
endothelium as it has been shown to regulate focal adhesion integrity via FAK (focal 
adhesion kinase) phosphorylation in endothelial cells, which is important in the 
regulation of tight junction and of macromolecule transport across endothelium (118). 
NO has also been suggested to interact with hemoglobin (Hb) when Hb is in the oxygen 
partial pressure (pO2)-dependent allosteric transition, be carried away by the red blood 
cells, and then released in the relatively ischemic tissues (119). NO subsequently induces 
vasodilation in oxygen-poor loci, diverting blood flow and thus increasing oxygen 
delivery to where it is most needed (120). Abnormalities in this process are associated 
with sickle cell anemia (121). 
In the immune system, NO plays a key role in mediating the bactericidal and 
tumoricidal actions of macrophages (79, 122-124). Inflammatory stimuli, such as 
endotoxin, stimulate the production of very large amounts of NO by the inducible NO 
synthase (iNOS), enabling macrophages to kill tumor cells and bacteria. Besides killing 
bacteria, NO also can inhibit viral replication (125-126). 
In the central nervous system (CNS), beginning with influential works of 
Garthwaite (127-128) and Snyder (129-131), NO has been identified as an important 
messenger molecule (132-136). The brain is capable of synthesizing NO (137-139). NO 
has been proposed to mediate neuronal plasticity, which underlies both development and 
information storage in the brain, by potentiating neurotransmitter release (91). NO 
signaling in the CNS appears to be essential for two forms of neuronal plasticity: 1) long-
term depression (LTD) in the cerebellum (138) and 2) long-term potentiation (LTP) in 
  
15
the hippocampus (140). Via its regulation of synaptic plasticity and neurotransmitter 
release, NO contributes to brain development, memory formation, and behavior (91). 
Excess levels of NO are neurotoxic and have been implicated in stroke and other 
neurodegenerative diseases in vivo (141). 
 
Nitric Oxide Synthase 
The specific action of NO depends on its enzymatic source, namely the nitric 
oxide synthase (NOS) enzyme family. Because NO cannot be released, stored, or 
inactivated by conventional regulatory mechanisms, NOS is one of the most highly 
regulated enzymes in biology. There are four major isoforms of NOS named after the 
tissue, cell source, and the order of which the isoform was characterized: 1) neuronal 
NOS (nNOS or NOS-1) (130, 142-143), 2) inducible NOS (iNOS or NOS-2) (144-147), 
3) endothelial NOS (eNOS or NOS-3) (148), and, more recently, 4) mitochondrial NOS 
(mtNOS) (149-152). 
All NOS isoforms are self-sufficient enzymes with two main functional domains 
fused into a single polypeptide (153). The C-terminal reductase domain contains the 
binding sites for NADPH (nicotinamide adenine dinucleotide phosphate), FAD (flavin 
adenine dinucleotide), and FMN (flavin mononucleotide). The N-terminal catalytic or 
oxygenase domain binds the redox cofactor, tetrahydrobiopterin (BH4), the heme 
prosthetic group, and the substrates L-arginine and oxygen (O2). This architecture is 
similar to that of cytochrome P-450BM-3 (154). Two NOS peptides dimerized in a head-
to-tail manner (Fig. 1.2) to ensure proper transfer of electrons from the reductase domain 







The structure of nitric oxide synthase (NOS) dimer. Arrows indicate the reaction 



















NOS oxidizes the guanidine group of L-arginine, in the presence of NADPH and 
O2, and in a process that consumes five electrons to produce NO with stoichiometric 
formation of L-citrulline. Thus, L-Nω-substituted arginine analogs, such as L-Nω-methyl-
arginine (L-NMA) and L-Nω-nitro-arginine (L-NNA), serve as NOS inhibitors (156). The 
catalysis process from arginine to NO takes two independent monooxygenase reaction 
steps. The first step is a two-electron oxidation of L-arginine to L-Nω-hydroxyarginine 
(LHA), utilizing 1 equivalents of NADPH and 1 equivalents O2, and releasing one 
molecule of water (157-158). The reducing equivalents from NADPH are transferred 
through FAD to FMN and finally to the heme (159). This hydroxylation reaction is 
accelerated by BH4, requires calmodulin (CaM) and Ca2+ as activators, and is blocked by 
carbon monoxide (CO) (157, 160-161). CaM is believed to facilitate the flow of electrons 
from the reductase domain to the monooxygenase domain and also from FAD to FMN 
(162). In the second step, one electron (or 0.5 equivalents of NADPH) is essential to form 
a second equivalent of reduced oxygen molecule (163), which then attacks the guanidine 
carbon of LHA to form a tetrahedral intermediate. This tetrahedral intermediate collapses 
to form the carbonyl group of L-citrulline with simultaneous expulsion of NO. The 
complete stoichiometry of NO synthesis by NOS therefore utilizes 1 mole of L-arginine, 
1.5 moles of NADPH, and 2 moles of O2 and produces 2 moles of water, 1 mole of L-
citrulline, and1 mole of NO (164). 
The involvement of BH4 and CaM is unique to NOS. The CaM/Ca2+ binding 
domain lies in the center of the enzyme. nNOS, eNOS, and mtNOS are expressed 
constitutively in mammals and their activities are regulated by CaM binding in a Ca2+ 
concentration dependent manner (165-166). Conversely, iNOS has CaM bound 
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permanently as an additional subunit and thus is not controlled by CaM binding nor it is 
Ca2+ concentration dependent, but is under transcriptional regulation instead (167). 
The mammalian NOS enzymes are products of distinct genes located on different 
chromosomes but they exhibit about 50 to 60% sequence homology with each other 
(164). nNOS is 155 kDa and found in peripheral and central neurons, noncholinergic and 
nonadrenergic neurons, endometrium, pancreatic islets, skeletal and smooth muscle, 
neutrophils and epithelium (92, 168). It has four splice variants and accounts for the 
majority of physiologic processes attributed to NO in the nervous system (169). iNOS is 
a 125 kDa protein expressed in macrophages, NK cells, neutrophils, smooth muscle, 
liver, heart, endothelium and other cell types (168). It is crucial for immune function and 
is inducible in response to glucocorticoids, cytokines, which include IL-1, TNF-α, IFNγ, 
and lipopolysaccharide (LPS), a bacterial cell-wall component that elicits symptoms of 
sepsis (170). eNOS is 125 kDa (168) and is the main isoform found in the endothelium. It 
is also found in smooth muscle, heart, brain, and other sites (168). mtNOS is 144-kDa 
and associates with the mitochondrial inner membrane (171). It produces NO to regulate 
mitochondrial respiration (172). 
Unlike nNOS and iNOS, which are mainly cytosolic, eNOS is predominantly 
localized to the plasma membrane (148). eNOS bioactivity and mobilization to specific 
organelles are highly regulated by multiple posttranslational modifications, such as 
acylation and phosphorylation. eNOS is irreversibly myristoylated at its N-terminal 
glycine (173). Myristoylation targets the enzyme to the cell membrane, where it is doubly 
palmitoylated at the N-terminal cysteine residues 15 and 26, a modification that further 
anchors eNOS to the plasmalemmal caveolae of endothelial cells (174). The N-
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myristoylation is sufficient and necessary for eNOS membrane association (175-176), 
palmitoylation (177-178), compartmentalization to the Golgi complex of cells, and most 
importantly, efficient NO synthesis (179). Palmitoylation is required for localization of 
eNOS in caveolae (180-181) and regulation of the frequency and magnitude of NO 
release in vivo in response to stimuli (182). In contrast to the myristoylation, 
palmitoylation and the consequential caveolar targeting are reversible and controllable as 
the thiopalmitoyl bonds are labile, hence creating an additional level of dynamic 
regulation of eNOS activity (183). Another dynamic control of eNOS involves various 
pathways of phosphorylation and dephosphorylation. eNOS phosphorylation is usually 
associated with its agonist-triggered translocation to the cytosol (184). eNOS has multiple 
phosphorylation sites, including Ser (Serine) 635 and Ser 1177, which are stimulatory, 
and Thr (Threonine) 495 and Ser 116, which are inhibitory (164). (Note that the 
numbering system refers to phosphorylation sites of human eNOS isoform.) The protein 
kinase Akt (protein kinase B) is a key enzyme that phosphorylates eNOS at Ser 1177 in 
response to agonists, resulting in eNOS released into the cytosol and activation at basal 
levels (185). Kinase Akt is activated by phosphoinositide-3-kinase (PI3K) (186), which 
in turn is activated by many eNOS agonists (i.e., vascular endothelial growth factor). 
eNOS Ser 635 represents a second stimulatory phosphorylation in respond to basal 
stimuli, such as shear stress, and agonists downstream of protein kinase A (187). In 
contrast, phosphorylation of eNOS at Thr 945 inhibits enzyme activity by preventing 
CaM binding (188). 
When eNOS is uncoupled from essential cofactors or is in the oxidized state, it 
produces superoxide (O2-) instead of NO (189). This situation has been demonstrated in 
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diseases, such as atherosclerosis, hypertension, hypercholesterolemia, and diabetes (189-
191). O2- and NO react rapidly, generating peroxynitrite (ONOO-), a potent oxidizing 
agent (192-194). This reaction further decreases NO availability while promoting lipid 
and protein oxidation (195). ONOO- itself plays a crucial role in eNOS uncoupling (196) 
by oxidizing the essential cofactor BH4 to the inactive pterin, 7,8-dihydrobiopterin (BH2) 
and removing zinc from the zinc-thiolate cluster (197). 
 
Dose-limiting Neuropsychiatric Toxicity of IL-2 Therapy 
 When clinical cardiovascular toxicities of IL-2 are attenuated with pressor agents 
and fluid administration, the effective dose escalation of IL-2 therapy is further limited by 
the onset of neuropsychiatric toxicity. In data reported in 1987, a large percentage of 
patients were found to develop striking neuropsychiatric changes after the onset of IL-2 
treatment, with 30–50% of patients experienced cognitive and behavioral changes (67). 
All of these patients returned to their baseline cognitive scores at follow-up. Based on our 
clinical experiences, perhaps as high as 40% of patients receiving IL-2 therapy have 
subtle neuropsychiatric changes, such as mental slowing or confusion, and approximately 
10–20% of patients develop more severe manifestations, such as agitation, hallucinations, 
or delusions. IL-2 induced neuropsychiatric toxicity is the least predictable and treatable 
compared to the cardiovascular toxicities. Management is generally by holding further 
doses of IL-2 and allowing patients to recover spontaneously. 
 In 1989, a study was conducted to look at the effects of IL-2 in the brain of 
patients with extracranial cancer without evidence of intracranial metastases using T2-
weighted MRI before and after IL-2 therapy (198). The results suggested a massive 
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increase of cerebral water content after IL-2 therapy in both the gray matter (12.6±7.3%) 
and white matter (17±6.2%). However, the range of these measurements actually varied 
from 3–48% and only 3 out of these 7 patients were mildly lethargic, raising questions 
concerning the accuracy of these data. The magnitude of these apparent cerebral water 
content increases are far greater than the magnitude of VLS measured in any other organ 
or even compared to the overall weight changes in the intact IL-2 treated animals or 
patients (approximately 6–8%), and thus are difficult to believe. 
 Previous studies in animal models showed increased permeability of horseradish 
peroxidase into the brain of cats and rats after a single bolus intravenous injection of 
recombinant IL-2, suggesting that IL-2 disrupted the blood-brain barrier (BBB) and 
cerebrovascular morphological integrity (199-200). Another study in a rat gliosarcoma 
model suggested that IL-2 increased the permeability of carbon-14-labeled 
aminoisobutyric acid from the BBB into the brain of tumor-bearing rat brains, but not in 
normal brains (201). Since tumors are known to have abnormal blood vessel permeability 
and accordingly could have contributed to the increased brain edema following IL-2 
treatment, the significance of this finding is uncertain. 
 The pathophysiology of IL-2 induced neuropsychiatric toxicity therefore remains 
poorly understood to date. Further efforts to study this toxicity have been limited by the 
availability of suitable experimental techniques and the technical challenges of 
performing dynamic contrast enhanced (DCE) MRI (magnetic resonance imaging) 
studies in critically ill patients, who normally are hospitalized in the ICU (intensive care 
unit). It would be quite difficult to perform DCE MRI studies once these patients display 
neuropsychiatric toxicity (delirium) as they are frequently receiving intravenous pressor 
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agents, intubated, and would not be stable enough to undergo lengthy MRI scans. 
Additionally, the gadolinium-based contrast agent used for DCE MRI may have an 
adverse effect for IL-2 treated patients, who usually develop a certain degree of acute 
renal dysfunction, as this agent has been shown to be associated with the development of 
nephrogenic fibrosing dermopathy (NFD) and nephrogenic systemic fibrosis (NSF) in 
patients with kidney dysfunction (202-204). 
It is likely that the “cytokine storm” released following IL-2 therapy induces 
changes in brain microvasculature, such as vascular leak and brain edema, which 
correlate to changes in the CNS function and thus trigger neuropsychiatric toxicity. 
Therefore, development and evaluation of a number of potential experimental methods to 
quantify changes on the brain blood vessels in a well-characterized IL-2 treatment murine 
model (83, 205) are required to delineate IL-2 induced neuropsychiatric toxicity. Once 
successful assays have been identified, the mechanisms of this toxicity can be 
determined. The role of NO and superoxide, the major players in systemic IL-2 induced 
VLS and hypotension, respectively, in IL-2 induced CNS changes is currently unknown. 
Detailed understanding of the mechanisms by which IL-2 induces neuropsychiatric 
toxicity will be useful in identifying possible pharmacologic inhibitors of this process to 
be used in patients, which may enable dose escalation of IL-2 treatment to achieve the 
effective high dose. In addition, this knowledge may also be broadly applicable to other 
conditions that give rise to an inflammatory “cytokine storm,” such as clinical 






 A potential implication of this study in other area of Biology is sepsis. Sepsis is a 
clinical syndrome characterized by a systemic response to an infection. There are roughly 
750,000 cases of sepsis annually in the United States (206-207). It is the leading cause of 
death among hospitalized patients in noncoronary ICU (208-209), causing an estimated 
215,000 deaths (9.3% of all deaths) in the United States and considerable morbidity, 
health care utilization, and cost (210). At the initial stages of sepsis, patients develop very 
similar clinical symptoms to the side effects of IL-2 therapy, particularly hypotension, 
VLS, and delirium (neuropsychiatric toxicity) (69). This is also associated with a very 
similar inflammatory “cytokine storm” (211-213). However, as sepsis progresses, 
patients experience irreversible organ failure, with a high incidence of acute tubular 
necrosis and irreversible hypotension, leading to death. In contrast, IL-2 dose limiting 
toxicities are reversible (i.e., complete resolution of renal function changes) following 
completion of IL-2 therapy and therefore may provide useful to model the early 
cardiovascular and neuropsychiatric effects of sepsis. 
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QUANTITATIVE ANALYSIS OF CYTOKINE-INDUCED 
VASCULAR TOXICITY AND VASCULAR LEAK IN 






A storm of inflammatory cytokines is released during treatment with pro-
inflammatory cytokines, such as interleukin-2 (IL-2), closely approximating changes 
initially observed during sepsis. These signals induce profound changes in neurologic 
function and cognition. Little is known about the mechanisms involved. We evaluated a 
number of experimental methods to quantify changes in brain blood vessel integrity in a 
well-characterized IL-2 treatment mouse model. Measurement of wet versus dry weight 
and direct measurement of small molecule accumulation (e.g. [3H]-H2O, sodium 
fluorescein) were not sensitive or reliable enough to detect small changes in mouse brain 
vascular permeability. Estimation of brain water content using proton density magnetic 
resonance imaging (MRI) measurements using a 7 T mouse MRI system was sensitive to 
1-2% changes in brain water content, but was difficult to reproduce in replicate 
experiments. Successful techniques included use of immunohistochemistry using specific 
endothelial markers to identify vasodilation in carefully matched regions of brain 
parenchyma and dynamic contrast enhanced (DCE) MRI. Both techniques indicated that 
IL-2 treatment induced vasodilation of the brain blood vessels. DCE MRI further showed 
a 2-fold increase in the brain blood vessel permeability to gadolinium in IL-2 treated 
mice compared to controls. Both immunohistochemistry and DCE MRI data suggested 
that IL-2 induced toxicity in the brain results from vasodilation of the brain blood vessels 
and increased microvascular permeability, resulting in perivascular edema. These 
experimental techniques provide us with the tools to further characterize the mechanism 






 Cytokines are important signaling proteins secreted by cells to regulate the 
immune system. Interleukin-2 (IL-2) is a 15 kDa cytokine which activates lymphocytes 
via its well-characterized heterotrimeric receptor (1-2). IL-2 plays an important role in 
the development of cell-mediated immunity (3). In the presence of properly processed 
and presented antigenic peptides, low concentrations (10-100 IU/ml) of IL-2 are essential 
for the activation of cytolytic lymphocytes and their clonal expansion (4). Additionally, 
when murine or human lymphocytes are exposed to high concentrations of IL-2 (> 600 
IU/ml) over 3-4 days either in vitro or in vivo, IL-2 rapidly activates a population of 
cytotoxic lymphocytes called lymphokine-activated killer (LAK) cells (5). LAK cells are 
termed “non-specific” killer cells as their cytotoxicity does not require antigen 
presentation in the context of self-MHC on target cells nor is it tumor-specific. LAK cells 
demonstrate cytotoxicity against almost all freshly isolated and cultured malignant cells 
(6-7), including multidrug-resistant tumor cells (8). 
 Activation of lymphocyte cytotoxicity against tumor cells in vitro by IL-2 led to 
evaluation of this cytokine as an anti-cancer therapy. In preclinical studies, concomitant 
IL-2 and LAK cells administrations on tumor-bearing mice resulted in regression of lung 
and liver metastases (9-10). Tumor regression in experimental mice was associated with 
prolonged survival (11-12). In clinical studies, high-dose i.v bolus IL-2 treatment induced 
5-7% complete and 10-15% partial responses in patients with malignant melanoma and 
metastatic renal cell carcinoma (13-14). Approximately 60% of complete responses to 




 Currently, IL-2 therapy is FDA approved for treatment of metastatic renal cell 
(RC) carcinoma and melanoma. IL-2 remains the only agent that can induce durable 
complete remissions of metastatic RC in approximately 5% of patients. Despite the 
dramatic increase in treatment options for metastatic RC in the past 4 years, including 
agents that inhibit vascular endothelial growth factor (VEGF) and mammalian target of 
rapamycin (mTOR) pathways (16), these agents predominantly induce disease arrest, 
requiring ongoing administration of expensive drugs to maintain a response. At the 
present time, IL-2 also remains the only clinically available remission-inducing agent for 
treatment of metastatic melanoma. 
 IL-2 therapy strongly induces synthesis of inflammatory cytokines termed a 
“cytokine storm” (17). These secondarily released cytokines, which include IFN-γ, tumor 
necrosis factor (TNFα, TNFβ), IL-1α, IL-1β, IL-5, and IL-6 (18-21) reach high levels in 
patient serum and are believed to trigger severe toxicities during IL-2 treatment. This 
pattern of cytokine secretion has strong similarities to the “cytokine storm” elicited by 
bacterial endotoxin (22-24). These secondarily released cytokines may also contribute to 
the therapeutic response to IL-2, as high dose steroids block IL-2 toxicity but also 
abrogate the therapeutic effectiveness of this agent (25). 
 The major dose-limiting toxicities of IL-2 are vascular leak syndrome (VLS) and 
hypotension. IL-2 induced VLS is generalized and dose dependent, characterized by loss 
of intravascular fluid into interstitial tissues. VLS is associated with marked fluid 
retention (weight gain), reversible renal dysfunction, and noncardiac pulmonary edema 
(26). IL-2 induced hypotension is due to a marked decrease in systemic vascular 




conjunction with VLS and intravascular volume depletion. It has also been recognized 
that reversible neuropsychiatric toxicity represents the third IL-2 dose-limiting toxicity. 
Denicoff et al. showed that there were striking neuropsychiatric changes in the majority 
of patients after the onset of IL-2 treatment, with 30-50% of patients experienced severe 
behavioral and cognitive changes (28). All patients returned to their baseline cognitive 
scores at follow-up (28). It should be noted that the pattern of hypotension, VLS, and 
delirium following IL-2 therapy in patients appears very similar to the clinical 
presentation of patients who have severe bacterial infection and septic shock (27). The 
major apparent difference is the complete resolution of renal function changes following 
completion of IL-2 therapy, unlike the high incidence of acute tubular necrosis during 
septic shock. It has become increasingly clear that even if hypotension and VLS can be 
attenuated, dose limitations related neuropsychiatric toxicity prevent effective IL-2 dose 
escalation. 
To date, the effects of inflammatory cytokines that trigger neuropsychiatric 
toxicity in the brain are not well understood. Moreover, technical challenges exist to 
study these effects after 4-5 days of IL-2 treatment (similar to treatment sequence used in 
human patients). Studies in patients and animal models have suggested that brain edema 
could play a role (29-32). However, Alexander et al. suggested that IL-2 induced brain 
edema occurred predominantly in tumor-bearing rat brain but not in normal brain (30). 
Since tumors are known to have abnormal blood vessel permeability, it is strongly 
believed that this could result in increased brain edema following IL-2 treatment. We 




effects on the non-tumor bearing central nervous system (CNS) using IL-2 treatment as a 
model in a well-characterized murine system (33-34). 
 
Materials and Methods 
Mice. Pathogen-free C3H/HeN mice were obtained from Charles River 
Laboratories. Mice were maintained under guidelines established by the Institutional 
Animal Care and Use Committee (IACUC). The IACUC also approved all the animal 
experimental protocols. Mice were age- and sex-matched in each experiment.   
IL-2 treatment. IL-2 treated mice received 150,000 IU of IL-2 (Aldesleukin 
Proleukin®; Novartis, Emeryville, CA) in 0.2 ml PBS (phosphate buffered saline) 
intraperitoneally (i.p.), b.i.d. (twice a day) for 5 days (10 doses total) in all experiments, 
except in experiments using MRI. For MRI studies, mice received 8 doses of 150,000 IU 
of IL-2 in 0.2 ml PBS i.p., b.i.d. (4 days). Control mice received no treatment, except in 
wet versus dry brain weight experiments, where control mice were treated with an 
equivalent volume of PBS (without IL-2). 
 Comparison of wet versus dry brain weight. Brains were harvested from each 
IL-2 treated and control mouse after 5 days of IL-2 and PBS treatment, respectively. Each 
brain was weighed before and after drying by Heto vacuum centrifuge (ATR, Laurel, 
Maryland) overnight in 60°C. The water content of the brain was calculated as: 
100. x 
wet weight
dry weight - wet weight
  water tissue% =  
 [125I]-labeled albumin extravasation in the mouse brain. Approximately 
100,000 counts per minute (cpm) of [125I]-labeled albumin (specific activity 1-5 µCi/µg) 




dose of IL-2. Mice were sacrificed 6 h after the last dose of IL-2 and the brains excised. 
Each brain was analyzed for albumin accumulation. Data was calculated as follow: 
.
mouse  thefrom recovered cpm total
 100% x cpmbrain 
  cpm % =  
 Tritiated water ([3H]-H2O) extravasation as a potential marker of IL-2 
induced VLS. IL-2 treated or control mice were injected with approximately 300,000 
cpm of [3H]-H2O in 100 µl PBS i.v. into the tail vein 2 h after the last dose of IL-2 or no 
treatment (control). Mice were then sacrificed at 4, 12, or 18 h after [3H]-H2O injection. 
The brain was harvested from each mouse, weighed, and homogenized in 1 ml PBS using 
Tissumizer (Tekmar, Cincinnati, OH). The homogenate (100 µl) was added into 2 ml 
scintillation fluid and quantified in a scintillation counter. To correct for tissue 
quenching, 100 µl brain homogenate from a normal mouse was directly mixed with 
300,000 cpm [3H]-H2O in 100 µl PBS and 2 ml scintillation fluid, and quantified in a 
scintillation counter. The cpm recovered was expressed as percentage of 300,000 cpm 
and was used to correct the apparent cpm from the IL-2 treated and control mouse brain 
homogenates. The [3H]-H2O extravasation in each brain homogenate of IL-2 and control 
mice was expressed as cpm per gram tissue as follow: 
.(g) weight  x tissue)(quenching  recovered cpm %
 100% x cpm homogenate
   tissuecpm/gram =  
Sodium fluorescein extravasation in mouse pleural fluid, lungs, and brain as 
an indicator of VLS. IL-2 treated or control mice were injected with 1.5 mg fluorescein 
sodium salt (NaFl; Sigma-Aldrich, St. Louis, MO) in 100 µl PBS i.v. via tail vein, 4 h 
after the last dose of IL-2. The mice were sacrificed 10 min after NaFl injection. The 




control mice did not have detectable pleural fluid, the thoracic cavity was irrigated with 
500 µl PBS, which was collected. The lungs and brain were also harvested and were 
homogenized in 1 ml PBS each, using Tissumizer (Tekmar, Cincinnati, OH). After 
centrifugation for 5 min, 100 µl of each homogenate was added in triplicate into a 96-
well plate. Also in triplicate, 100 µl of the pleural fluid from each mouse was transferred 
into another 96-well plate. Plates were read using a Synergy 2 microplate reader (BioTek 
Instruments, Winooski, Vermont) at 519 nm emission and 495 nm excitation 
wavelengths. For the pleural fluid, the fluorescence was quantified using a standard curve 
and multiplied by the total volume recovered to calculate the total amount of NaFl (in µg) 
that leaked into the pleural fluid. In lung or brain homogenates, the fluorescence was 
corrected for tissue quenching and quantified using a standard curve. Data were 
expressed as µg NaFl/organ based on the total volume of homogenate. 
Evaluation of brain blood vessel morphology using immunohistochemistry. 
Brains were excised from IL-2 treated or control mice. Each brain was embedded in 
Tissue-Tek O.C.T. Compound (Ted Pella, Redding, CA) and frozen at -20 °C overnight 
before sectioning. Matched sections (6 µm) of the mid-brain (Fig. 2.1) were dual-stained 
with Isolectin GS-IB4 (Iso-B4) from Griffonia simplicifolia, conjugated to Alexa Fluor® 
568 (Molecular Probes, Eugene, OR) and rabbit anti-human von Willebrand Factor 
(vWF; Sigma-Aldrich, St. Louis, MO), followed by a secondary Dichlorotriazinyl-
aminofluorescein (DTAF)-conjugated donkey anti-rabbit IgG (Jackson ImmunoResearch 
Laboratories, West Grove, PA). Digital images of 20 specific regions of interest (4 
different areas in the left cortex, right cortex, left striatum, right striatum, and the cerebral 








Cross section drawing of the mouse mid-brain section, which includes the cortex and 
striatum anatomic regions, derived from Dorr et al. (35). Inset figure represents the 
position at which the tissue slice was taken (Bregma 0.62-0.38 mm). The drawing shows 
the name of major cerebral vasculature structures found in the specific section. azPA = 
azygos pericallosal artery. Boxes show the locations of 19-20 digital images obtained 
from each section for vessel analysis. On the right are representative sections from the 
control and IL-2 treated mice, which were matched as closely as possible to the drawing 
on the left, stained with hematoxylin and eosin. These representative sections are located 













fluorescent microscope mounted with Olympus DP70 camera. Using ImageJ software 
(National Institutes of Health, NIH), the blood vessels (dual stained tubular structures) in 
each digital image were manually outlined and analyzed for the total number and average 
size of vessels. 
Evaluation of brain water content using MRI proton density measurements. 
MRI was performed using a Bruker 7T/20 scanner, a 3.5 cm ID (inner diameter) 
quadrature transceiver coil, and a 7 cm ID unshielded gradient. Mice were anesthetized 
by i.p. injection of 80 mg/kg ketamine (Vetalar®; Aveco, Fort Dodge, IA) and 
maintained inside the magnet using isoflurane (Attane™; Minrad, Bethlehem, PA) 
inhalational anesthesia as required. Mouse temperature inside the magnet was maintained 
using a circulating warm water system. Each mouse was scanned both before and after 
IL-2 treatment. Proton density MRI was sequenced using a Fast Spin Echo sequence with 
a repetition time (TR) of 24 s, an echo time (TE) of 7.5 ms, and an echo train length of 4. 
Slice thickness was 1 mm, field of view was 2x2 cm2, and matrix size was 256x192 
pixels. The slice thickness and matrix size were optimized to detect proton density 
changes in the mouse brain of > 1%. The total scan time was 14 min and 24 s. Regions of 
interest (ROIs) were drawn manually on matched pre- and post-IL-2 mouse’s brain 
DICOM (Digital Imaging and Communications in Medicine) images using OsiriX 
imaging software (http://www.osirix-viewer.com/). The signal intensity (SI) of each brain 
slice was normalized using a set of phantoms (60-100% H2O/D2O in 10% increment) and 
expressed as the percentage of proton density (%PD). We averaged the %PD over 8 MRI 





Dynamic contrast enhanced (DCE) MRI. The MRI system and anesthesia were 
described above. Each mouse was scanned before and after IL-2 treatment, serving as its 
own control. Prior to imaging, the tail vein of each mouse was catheterized using a 30-
gauge needle connected to an approximately 1 m long, 0.28 mm ID tube pre-filled with 
heparinized PBS (approximately 100 µl). DCE-MRI was performed using 2D-FLASH 
(Fast Low-Angle Shot): TR = 93.5 ms, TE = 3.1 ms, flip angel = 30 º, FOV = 2 x 2 cm, 
matrix = 128 x 128, slice thickness = 1 mm, number of slices = 11, single scan time = 9 s, 
number of repetitions = 54. After the first 5 repetitions, 0.1 mmol/kg contrast agent 
(gadobenate dimeglumine; MultiHance®, Bracco) was administered by bolus injection 
via the catheter. Customized MATLAB programs (The MathWorks, Natick, MA) were 
used to calculate the SI of the whole brain ROI in matched mid-brain sections of pre- and 
post-IL-2 DICOM images. The signal intensities of the left and right maxillary veins 
were averaged to derive the contrast agent concentrations in the blood pool. The average 
SI of ROI before contrast agent injection was used as the baseline and subtracted from all 
SI after contrast agent injection to calculate the increase in SI (∆SI). ∆SI was assumed to 
be proportional to the change in contrast agent concentration when a low concentration of 
contrast agent was used (36). A two-compartment model was originally developed by 
Shames et al. (36) to characterize tumor vasculature and adapted by Feng et al. (37) to 
calculate the tumor fractional plasma volume (fPV), endothelium transfer coefficient 
(KPS), and permeability surface area product (PS). This method was similarly used to 
characterize the brain microvasculature. 
Statistical analysis. All data are expressed as mean ± standard error of the mean 




test using GraphPad PRISM software (GraphPad Software, La Jolla, CA). The 
immunohistochemistry data were analyzed using 2-factor analysis of variance (ANOVA) 
with a blocking factor for region of the brain. All the other data were analyzed using 2-
sample Student’s 2-tailed t-test. A p-value ≤ 0.05 was considered significant. 
 
Results 
Comparison of wet versus dry brain weight in IL-2 treated mice. Difference 
in wet versus dry tissue weight is assumed to be approximately the volume of interstitial 
fluid in the tissue. It was not certain whether this technique was sensitive enough to 
detect the small fluid shifts that were likely in the mouse brain related to cytokine 
treatment. We excised brains from IL-2 treated or control mice (treated with an 
equivalent volume of PBS) after 5 days of treatment and weighed each brain before and 
after drying by speed vacuum. The average brain water content of IL-2 treated mice was 
43.05±1.84% of the wet weight while the control mice had a mean brain water content of 
42.6±1.524% (p = 0.85; Fig. 2.2). It became clear from these results that this method 
lacked sensitivity to identify relatively small changes in the brain water content of mice 
related to IL-2 treatment. 
 [125I]-labeled albumin extravasation in the mouse brain. Radioactive labeled 
[125I]-bovine serum albumin has often been used to study IL-2 induced VLS in mice 
tissues (38). However, it had not been quantified as a VLS marker in the mouse brain. To 
test this, we injected IL-2 treated or control mice with [125I]-labeled albumin bolus via tail 
vein. After 4 h, mice were sacrificed and the brains excised. The amount of [125I]-labeled 








Direct comparison of wet versus dry brain weight from IL-2 treated mice. Brains were 
excised from IL-2 treated and control mice (n = 9). Each mouse brain was weighed 
before and after drying in a vacuum centrifuge overnight in 60 °C. The wet and dry 
weight difference was expressed as a percentage of wet weight. Error bars represent 































amount of [125I]-labeled albumin recovered from the mouse. Analysis of [125I]-labeled 
albumin accumulation in the brain showed no significant increase following IL-2 
treatment (p = 0.17; Fig. 2.3). The amount of [125I]-labeled albumin recovered from the 
brain of IL-2 treated mice was 0.2172±0.04% while the control mice had 0.1364±0.04%. 
The small percentage of [125I]-labeled albumin recovered from the mouse brain 
demonstrated that this method also lacked the sensitivity to measure a small increase in 
[125I]-labeled albumin extravasation in the mouse brain induced by IL-2. 
Tritiated water ([3H]-H2O) extravasation as a potential marker of IL-2 
induced VLS. We hypothesized that vascular leak in the brain should correlate with the 
ability of water molecules (H2O) to cross the BBB. To test [3H]-H2O as a potential 
marker of IL-2 induced fluid shifts in the mouse brain, IL-2 treated or control mice were 
injected with [3H]-H2O bolus via tail vein. At specified times, mice were sacrificed and 
the brain excised. Each brain was weighed and homogenized. The homogenate was 
quantified in a scintillation counter, and corrected for quenching of counts by tissue 
homogenate. At 4 and 12 h after the last IL-2 dose, significant [3H]-H2O retention in the 
brain of IL-2 treated mice could not be detected compared to the control mice (Fig. 2.4). 
At 4 h after the last IL-2 dose, there were 787.3±36.48 cpm [3H]-H2O/g brain in the IL-2 
treated mice compared to 742.7±17.39 cpm [3H]-H2O/g brain in the control mice (p = 
0.332). By 12 h, there were 713±37.29 cpm [3H]-H2O/g brain in the IL-2 treated mice 
and 653.5±24.28 cpm [3H]-H2O/g brain in the control mice (p = 0.2024). There was a 
trend toward increased [3H]-H2O retention in the brain of IL-2 treated mice at 18 h 
(810.8±70.82 cpm [3H]-H2O/g brain) compared to the control mice (552±24.03 cpm [3H]-








Evaluation of IL-2 induced vascular leak in the brain using [125I]-labeled albumin. Mice 
(n = 6) were injected with approximately 100,000 cpm of [125I]-labeled albumin in 100 µl 
PBS via tail vein 2 h after the last dose of IL-2 or no treatment (control). After 4 h, mice 
were sacrificed, the brains excised and analyzed for [125I]-labeled albumin accumulation. 
The results were expressed as percentage of radiolabeled albumin recovered from the 



























Evaluation of changes in brain water content using tritiated water ([3H]-H2O). Two hours 
after the last IL-2 dose or no treatment (control), mice (n = 3 at 4 h, n = 8 at 12 and 18 h) 
were injected with ~300,000 cpm [3H]-H2O in 100 µl PBS via tail vein. The brain was 
harvested from each cohort of control and IL-2-treated mice at the specified time (4 h, 12 
h, or 18 h) after [3H]-H2O injection. Brains were homogenized and 100 µl was counted in 
2 ml scintillation fluid on a scintillation counter. The results were corrected for tissue 























treatment schedule, this technique exhibited quite a bit of variability between 
experiments. This led us to conclude that measurement of [3H]-H2O retention was not a 
reliable means of measuring IL-2 induced fluid shifts in the mouse brain. 
 Measurement of Sodium Fluorescein (NaFl) extravasation in the mouse 
pleural fluid, lungs, and brain. NaFl is a small fluorescent molecule (MW = 376.27). 
This probe may provide increased sensitivity for detection of BBB disruption induced by 
IL-2 and decrease tissue quenching and volume of distribution problems related to the 
use of [3H]-H2O. We evaluated NaFl as an indicator for IL-2 induced VLS, based on its 
prior use as a marker for fluorescence imaging of BBB disruption in rats (39-40). Control 
and IL-2 treated mice were injected with 1.5 mg NaFl in 100 µl PBS via tail vein and 
sacrificed after 10 min. Pleural fluid was collected directly from the thoracic cavity of IL-
2 treated mice whereas the thoracic cavity of the control mice was irrigated with 500 µl 
PBS, which was then collected. The entire recovered volume was quantified. 
Fluorescence was measured by spectrofluorometer. Using a standard curve, the 
concentration of NaFl recovered from each mouse was quantified. By multiplying the 
concentration of NaFl by the total volume of the fluid recovered, we calculated the total 
amount of NaFl leak. IL-2 treatment increased NaFl extravasation into the pleural space 
by 9-fold (9.59±0.82 µg total NaFl) compared to the control mice (1.09±0.13 µg total 
NaFl), p < 0.0001 (Fig. 2.5A). 
 In order to evaluate the usefulness of this technique for solid organs, the lungs and 
brain from these mice were excised. Each tissue was homogenized in 1 ml PBS, and the 
amount of NaFl in the homogenate quantified. Following correction of tissue-specific 




mice. There was no detectable difference compared to NaFl content in lungs of the 
control mice (8.88±1.21 µg total NaFl, p = 0.35; Fig. 2.5B). There was also no detectable 
difference in the amount of total NaFl in the brains of IL-2 treated mice (1.06±0.05 µg 
total NaFl) compared to the control (1.14±0.06 µg total NaFl), p = 0.34 (Fig. 2.5C). This 
method proved useful in demonstrating small molecule leak resulting in pleural effusions, 
but not into solid organs of IL-2 treated mice. Perfusion of mice with saline to decrease 
intravascular NaFl retention did not seem to influence results in the brain (data not 
shown). 
 Evaluation of brain blood vessel morphology using immunohistochemistry. It 
is well known that nitric oxide (NO) produced by endothelial cells or from 
pharmacologic donors induces vasodilation (41-43). We therefore evaluated whether 
vasodilation could be identified in brain blood vessels via immunohistochemistry. We 
prepared 6 µm sections from carefully defined anatomic region of the mouse mid-brain 
(Fig. 2.1) chosen to reflect highly vascular areas based on a study by Dorr et al. (35). 
Areas selected included the cerebral fissure, the striatum and the cortex in the highly 
vascularized anatomic region shown (Fig. 2.1). We tested a number of putative 
endothelial cell-specific antibodies, CD34, CD144 (VE-cadherin), and anti-von 
Willebrand Factor (vWF). All of them showed speckled endothelial cell staining (data not 
shown). As vWF is specifically produced in blood vessels, this marker was selected. 
However, the granular nature of the stain made it difficult to outline vessels to measure 
the area. Isolectin GS-IB4 (Iso-B4) demonstrates strong staining of perivascular cells. 
Unfortunately, Iso-B4 is also known to stain brain microglial cells. By using dual staining 








Evaluation of blood vessel permeability using sodium fluorescein (NaFl) in the mouse A) 
pleural fluid, B) lungs, and C) brain. Mice (n = 5) were injected with 1.5 mg NaFl in 100 
µl PBS via tail vein 4 h after the last IL-2 dose or no treatment (control). After 10 min, 
mice were sacrificed. The pleural fluid was collected and the brains and lungs were 
excised from each mouse. The lungs and brain were homogenized in 1 ml PBS and 100 
µl of each homogenate or 100 µl of the collected pleural fluid was quantified by 
spectrofluorometer. The total amount (µg) of NaFl in each sample was calculated by 
using a standard curve, corrected for tissue quenching, and then multiplied by the total 
























mouse brain section. We obtained twenty 20x magnification digital images from precise 
anatomic locations of the brain section (4 of each left cortex area, right cortex, left 
striatum, right striatum, and the cerebral fissure) using fluorescence microscopy and 
analyzed each image for the numbers and size of blood vessels. The analysis showed that 
the average size of vessels in the brain was almost 2-fold larger in the IL-2 treated mice 
(37750.53±5598 pixel2) compared to the control mice (20652.85±5598 pixel2), p = 
0.0389 (Fig. 2.6A), while the number of vessels in the brain of IL-2 treated mice 
(8.082±1.83) were not significantly different compared to the control mice (7.343±1.83), 
p = 0.7765 (Fig. 2.6B). The number of blood vessels was not expected to change during 5 
days of IL-2 treatment. These results suggest that IL-2 strongly induced vasodilation of 
the brain blood vessels. 
 Evaluation of brain water content using MRI proton density. Intrinsic MR 
parameters, such as longitudinal (T1) and transverse (T2) relaxation times, are sensitive to 
changes in the proton density and therefore the water content of tissues. Therefore, MRI 
proton density (PD) provides a potential noninvasive technique to quantify changes in the 
brain water content induced by cytokine treatment. A prior study in IL-2 treated patients 
using a T2-weighted MRI had suggested that particularly large changes in brain MR 
signal intensity were induced by IL-2 treatment (29). However, this study showed an 
extremely wide percentage range (3-48%) of the changes in the cerebral water content, 
raising questions as to the accuracy and reproducibility of this determination. We 
developed a high resolution murine imaging technique to critically assess MRI quantified 
PD changes in the brains of IL-2 treated mice. Imaging phantoms were prepared 








Immunostaining of brain sections to evaluate endothelial cell morphology. Brains were 
excised from IL-2 treated and control mice (n = 3). Sections (6 µm-thick) were carefully 
prepared to identify specific anatomic regions of the mid-brain.  Each frozen section was 
dual-stained with Iso-B4 and anti-vWF to identify blood vessels and exclude microglial 
cells. The blood vessels were manually outlined on 20 digitized fluorescence images of 
each stained section and analyzed for A) the average size of vessels and B) total number 























references. We scanned anesthetized mice both before and after IL-2 treatment using 
MRI PD sequence using a 7T Bruker MRI system with a mouse-specific coil. We 
established that this sequence was sensitive enough to detect an approximate 1% change 
in PD in the mouse brain. PD was calculated using a ratio of the signal intensity (SI) from 
the manually drawn ROI (region of interest) around the whole mouse brain with that of 
the phantom SI. We averaged PD over 8 matched brain slices of pre- and post-IL-2 
DICOM images for each mouse. The results of this experiment (Fig. 2.7) established that 
there was no significant difference (p = 0.7892) in MRI proton density of IL-2 treated 
mice (73.31±0.7) compared to before receiving IL-2 treatment (73.65±0.7). We also 
found that results obtained with this technique varied markedly between experiments. We 
concluded that the MRI PD sequence was too inconsistent to provide useful information 
concerning the small, most likely perivascular changes in mouse brain water content 
related to IL-2 administration. 
 Dynamic contrast-enhanced (DCE) MRI. DCE MRI is a quantitative, 
noninvasive technique to measure vascular permeability using a gadolinium-based 
contrast agent. DCE MRI has often been used clinically to assess tumor angiogenesis 
based on tumor vascular permeability. This technique provides physiologically 
meaningful quantitative assessment of vascular parameters, such as fractional plasma 
volume (fPV), endothelial transfer coefficient (KPS), and permeability surface area product 
(PS) (44).  fPV describes the plasma volume of the blood vessels in that tissue. KPS 
reflects the permeability of the contrast agent from the blood vessels to the extravascular 
and extracellular space (EES) of the tissue. PS describes the surface area of the 







Evaluation of proton density in the brains of IL-2 treated mice using a 7T MRI system. 
Mice (n = 5) were scanned both before and after 4 days of IL-2 treatment (150,000 U i.p, 
b.i.d.) using a MRI PD sequence as described in the Materials and Methods. Regions of 
interest were manually drawn on matched sections of mouse brain using OsiriX software 
and expressed as % proton density (PD) based on the phantoms (created using 60-100% 
H2O/D2O in 10% increment). The %PD was averaged over 8 slices for each mouse and 























MRI to evaluate the brain microvasculature of IL-2 treated mice. Anesthetized mice were 
scanned before and after IL-2 treatment using 2D-FLASH MRI sequence. This MRI 
sequence provides good spatial resolution and has the advantage of allowing rapid 
scanning. We calculated SI from a manually drawn ROI on a selected mid-brain section 
of each mouse, matched between pre- and post-IL-2 images, using customized MATLAB 
programs. The contrast agent concentration in the blood pool was established by 
averaging the SI from the left and right maxillary veins. We used a two-compartment 
model consisting of the brain plasma compartment and the EES to calculate fPV, KPS, and 
PS as described previously by Feng et al. (37). DCE MRI data established a 2-fold 
increase of fPV in the mice brain after receiving IL-2 treatment (p = 0.0285; Fig. 2.8A). 
The fPV in the post-IL-2 mice brain was 3.048±0.56 whereas in the pre-IL-2 mice brain 
was 1.554±0.21. This result suggested vasodilation of the brain blood vessels following 
IL-2 treatment, independently verifying the results of brain immunohistochemical 
staining. DCE MRI also showed that IL-2 significantly increased brain microvascular 
permeability to the contrast agent by 2-fold (p = 0.0079; Fig. 2.8B). KPS value in the mice 
brain after receiving IL-2 treatment was 0.4305±0.05 ml/min/100 cm3 whereas prior to 
IL-2 treatment was 0.2039±0.04 ml/min/100 cm3. Finally, the PS was 1.275±0.22 
ml/min/100 cm3 in the mice after receiving IL-2 while in the mice prior to the IL-2 
treatment was 0.2953±0.05 ml/min/100 cm3 (Fig. 2.8C). These data suggested a 
significant (p = 0.0083) 4-fold increase in the blood vessel surface area that was “leaky” 
to the contrast agent after IL-2 treatment. These changes in brain vascular parameters 
identified using DCE MRI established that IL-2 induces vasodilation of the brain blood 








Evaluation of IL-2 induced changes in the brain blood vessel permeability by dynamic 
contrast enhanced (DCE) MRI. Mice (n = 5) were scanned both before and after 4 days of 
IL-2 treatment (150,000 U i.p, b.i.d.) using 2D-FLASH MRI sequence as described in the 
Materials and Methods. After baseline imaging, 0.1 mmol/kg contrast agent was 
administered by bolus injection via tail vein catheterization. Customized MATLAB 
programs were used to calculate signal intensities from manually drawn ROI on a 
selected 1-mm mid-brain section of each mouse. We averaged the left and right maxillary 
veins to derive the contrast agent concentration in the blood pool and a two-compartment 
model was used to calculate A) fractional plasma volume (fPV), B) endothelium transfer 
coefficient (KPS), and C) permeability surface area product (PS). IL-2 treatment 
























Sepsis causes an estimated 215,000 deaths (9.3% of all deaths) in the US and 
considerable morbidity, mortality, health care utilization, and cost (45). Patients of early 
stages of sepsis develop similar symptoms to the side effects of IL-2 therapy, particularly 
hypotension, vascular leak, and neuropsychiatric toxicity (i.e., delirium). However, as 
sepsis progresses, patients experience irreversible organ failure, and eventually death. IL-
2 dose limiting toxicities are reversible and therefore may provide useful to model the 
early cardiovascular and neuropsychiatric effects of sepsis. 
 A poorly characterized percentage of patients receiving IL-2 therapy become 
mentally slowed or confused (perhaps as high as 40% in our experience) and 
approximately 10-20% of patients become agitated, sometimes with hallucinations or 
delusions. The pathophysiology of IL-2 induced neuropsychiatric toxicity remains poorly 
understood. It is likely that the “cytokine storm” released during IL-2 treatment and 
sepsis induces changes in brain microvasculature, such as vascular leak and brain edema, 
which relate to changes in the CNS function and thus cause neuropsychiatric toxicity. We 
therefore evaluated a number of potential experimental methods to quantify the effect of 
cytokine-induced changes on brain blood vessels, utilizing a well-characterized IL-2 
treatment murine model. 
 We have performed extensive studies of different doses of IL-2 in mice. The dose 
of IL-2 chosen for the current experiments (150-180,000 IU twice daily) is based on dose 
and time response studies previously performed in our lab to evaluate changes in 
systemic vascular permeability and hypotension in our murine model, and is 




designed to mirror the effect of massive doses of IL-2 administered to human patients 
(600,000 IU/kg q8h for 14 doses). 
 Previous studies have been attempted to delineate the mechanisms of IL-2 dose-
limiting toxicities with the eventual goal of blocking these toxicities without affecting the 
therapeutic effectiveness of IL-2. Nitric oxide (NO) and superoxide have been identified 
as key players in systemic IL-2 induced VLS and hypotension, respectively (33, 46). The 
role of these mediators in the brain is currently unknown. Saris et al. have looked at the 
effects of IL-2 in the brain of patients with extracranial cancer without evidence of 
intracranial metastases (29). This study used T2-weighted MRI to look at changes in 
signal intensities in the brain, which correlated with changes in cerebral water content, 
before and after IL-2 therapy. Even though their results suggested a massive increase of 
cerebral water content in both the white matter (17±6.2%) and gray matter (12.6±7.3%) 
after IL-2 therapy, only 3 out of these 7 patients were mildly lethargic (29). Moreover, 
the range of these measurements varied from 3% to 48%, raising questions concerning 
the accuracy of these determinations in critically ill patients. The magnitude of these 
apparent proton density increases are difficult to believe, since they are far greater 
magnitude than vascular leak measured in any other organ or even overall weight 
changes in the intact IL-2 treated animals or patients. 
 In cats and rats, a single bolus intravenous injection of recombinant IL-2 
increased permeability of horseradish peroxidase into the brain, suggesting that IL-2 
disrupted the blood-brain barrier (BBB) and cerebrovascular morphological integrity (31-
32). A study on the effect of IL-2 on the BBB in gliosarcoma rat model suggested that IL-




into the brain in tumor-bearing rat brain but not in normal brain (30). However, tumors 
are known to have abnormal blood vessel permeability and are suspected of contributing 
to increased brain edema following IL-2 treatment, raising uncertainty concerning the 
significance of this finding. 
Our results showed no detectable differences in the mouse brain interstitial fluid 
between IL-2 treated and controls measured using wet versus dry brain weight (Fig. 2.2), 
quantification of radioactive labeled [125I]-bovine serum albumin (Fig. 2.3), tritiated 
water retention (Fig. 2.4) or fluorescence marker (Fig. 2.5C), and MRI proton density 
measurements (Fig. 2.7). This is likely due to the small magnitude of changes in brain 
water content or edema (<5%) that produces symptoms. In addition, quenching of the 
signal related to tritiated water, and to some degree tissue fluorescence (for NaFl) 
required compensation, further decreasing sensitivity. Another problem was that even in 
syngeneic mice treated on a very precise schedule, there was substantial inter-experiment 
variability. This further limited the usefulness of these techniques. 
However, our mouse brain immunohistochemical staining (Fig. 2.6A) and DCE 
MRI fPV values (Fig. 2.8A) independently demonstrated a 2-fold increase in the area and 
volume of the brain blood vessels, respectively, in IL-2 treated mice. These data indicated 
vasodilation of the brain blood vessels. Further characterization of the brain blood vessels 
by DCE MRI also showed a 2-fold increase of the mouse brain blood vessel permeability 
(KPS) to the contrast agent after IL-2 treatment (Fig. 2.8B). These increases in DCE MRI 
fPV and KPS values induced by IL-2 resulted in a 4-fold increase in the surface area of the 




We established that additional methods quantifying changes in brain interstitial 
fluid induced by cytokines in mice were not informative. We used microscopy to evaluate 
changes in fixable Alexa Fluor® 594-conjugated dextran (10,000 MW; Molecular 
Probes, Oregon) or Hoechst 33342 (616 MW; Aldrich Chem., Milwaukee) staining in the 
mouse brain (47) following IL-2 treatment (data not shown). None of these dyes were 
able to accurately quantify the small changes in brain interstitial fluid in mice related to 
IL-2 therapy. A normal mouse brain weighs about 0.5 g. Approximately 5% of the mouse 
brain weight (25 mg) represents interstitial/or extracellular fluid. Assuming that IL-2 
changes the mouse brain fluid content by 5-7%, a magnitude similar to the maximum 
increase in the mouse body weight during IL-2 treatment (data not shown), only about 1-
2 mg changes in weight or 1-2 µl changes in water volume are predicted to occur within 
the brain parenchyma. This miniscule amount could not be measured accurately using 
small molecule probes in homogenates of brain tissue or by microscopy. 
Despite failure to measure changes in the brain interstitial fluid after IL-2 therapy 
using NaFl, a significant 9-fold increase of NaFl was detected in pleural fluid of IL-2 
treated mice, p = 0.0003 (Fig. 2.5A), consistent with the noncardiac pulmonary edema 
and vascular leak experienced by patients receiving IL-2 therapy (26). However, we did 
not detect a significant difference of NaFl in the lung parenchyma after IL-2 treatment, p 
= 0.47 (Fig. 2.5B). Our studies indicate that NaFl quantification in pleural fluid appears 
to be a sensitive marker for systemic VLS in mice. This result appears to contradict prior 
studies of IL-2 induced VLS in the mouse lungs, which have been described using [125I]-




over of pleural fluid during excision of lungs in these experiments could induce a 
significant error. 
 Dual staining using anti-von Willebrand Factor (vWF) and isolectin GS-IB4 (Iso-
B4) specifically identifies the blood vessels in the mouse brain sections and was able to 
show brain blood vessel vasodilation induced by IL-2. One difficulty using this technique 
was to closely match all the brain cross-sections. We chose to analyze a section through 
the mid-brain including the cerebral cortex and striatum as both of these regions are gray 
matter, which consists of neuronal cell bodies, glial cells (oligodendrocytes and 
astroglia), neuropil (axons and dendrites), and capillary blood vessels. The striatum is 
best known for its role in cognitive processes while the cerebral cortex plays an essential 
role in attention, thought, memory, perceptual awareness, and consciousness. Previous 
studies in humans receiving IL-2 have suggested that these processes are significantly 
affected during IL-2 induced neuropsychiatric toxicity (28). Vasodilation in these specific 
anatomic regions therefore appears to strongly correlate with the IL-2 induced behavior 
and cognitive changes in treated patients. 
 Although we established a MRI sequence that was sensitive enough to detect 
approximately 1% change in phantoms using a 7T Bruker MRI system with a mouse-
specific coil, the PD changes in the mouse brain obtained with this technique were 
markedly different between replicate experiments. There are four potential issues why the 
MRI PD data exhibited such variation. First, it was difficult to completely align matched 
MRI coronal sections between pre- and post-IL-2 scans of each individual mouse. 
Second, we obtained 1-mm thick axial slices throughout the mouse brain. This thickness 




the sensitivity to measure small or localized changes of PD in the mouse brain. This is 
particularly relevant, since the permeability surface coefficient derived from DCE-MRI 
studies suggests that IL-2 induced changes in brain water content may be perivascular 
rather than evenly distributed throughout the brain parenchyma. The third potential 
problem using a 7T MRI may relate to inhomogeneity of the static and rotating magnetic 
fields (B0 and B1). We attempted to minimize these effects by standardized placement of 
the mouse and phantoms within the coil. The final caveat was that manual segmentation 
of the mouse brain on the images proved somewhat error prone. It is not possible to 
perfectly outline the brain, resulting in some variability due to inadvertent inclusions of 
CSF water density pixels. With a relatively large standard deviation of the SI, the 
accuracy of measuring proton density changes is further decreased. It is possible that an 
automated MATLAB data extraction algorithm could be written to better exclude this 
potential artifact and improve reproducibility. 
 As measurement of IL-2 induced changes in average mouse brain water content 
proved problematic, a quantitative assessment of the vascular permeability to a small 
molecule contrast agent over a period of time using DCE MRI seemed more effective. 
DCE MRI is noninvasive, which allows for the same mice being scanned before and after 
IL-2 treatment, eliminating brain variability between individual mice. The 2D-FLASH 
MRI sequence provided a good spatial resolution and was fast. One major advantage 
using this technique is simultaneous characterization of the mouse brain blood vessel area 
and permeability to a small molecular probe. This method can be used to show increased 
vascular permeability changes in other tissues, such as liver and lungs. For example, 




51). However, this adds additional technical challenges, such as compensation for organ 
movement due to breathing and heartbeat. Gating will be required and this prolongs 
scanning time, which may be detrimental in critically ill and unstable mice or patients. 
 To our knowledge, there are currently no published data of DCE MRI technique 
in patients with sepsis or receiving inflammatory cytokine administration. These 
processes are virtually impossible to study in critically ill human patients, who generally 
are hospitalized in intensive care units. Once these patients exhibit neuropsychiatric 
toxicity (delirium), it would be quite difficult to perform DCE MRI studies, as they are 
frequently intubated and receiving intravenous pressor agents and would not be stable 
enough to undergo MRI studies. Another concern is that gadolinium-based contrast 
agent, which is mainly used for DCE MRI, has been shown to be associated with the 
development of nephrogenic fibrosing dermopathy (NFD) and nephrogenic systemic 
fibrosis (NSF) in patients with kidney dysfunction (52-54). Therefore, this contrast agent 
may have an adverse effect in IL-2 treated or sepsis patients, who usually have at least 
some element of acute renal dysfunction. 
In conclusion, we were able to show that IL-2 induced vasodilation of the brain 
blood vessels and increased permeability of these vessels in mice, suggesting that IL-2 
induced neuropsychiatric toxicity may correlate with small blood vessel vasodilation in 
the brain as well as small increases in brain water content (edema). We are currently 
using these methods to evaluate the neuropsychiatric toxicity of IL-2 induced vascular 
leak in the brain. The long term goal is to identify pharmacologic inhibitors that block 
hypotension, vascular leak, and neuropsychiatric toxicity for testing in patients following 
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NEUROLOGIC TOXICITY CORRELATES WITH ENDOTHELIAL 
NITRIC OXIDE SYNTHASE INDUCED CEREBRAL 
VASODILATION AND MICROVASCULAR 






 Interleukin-2 (IL-2) is the only agent that produces durable remissions in 5–10% 
of metastatic melanoma and renal cancer patients. Neuropsychiatric toxicity is frequent 
and dose-limiting. The pathophysiology is not currently understood. Behavioral changes 
following IL-2 therapy were quantified in a murine model, demonstrating that 
spontaneous movement, rearing, and grooming were decreased by day 2 of IL-2. Motor 
strength was affected by day 4. Immunohistochemical and DCE MRI evaluation of the 
brain vasculature demonstrated that IL-2 induced vasodilation and increased permeability 
by 2- to 4-fold on day 4. We hypothesized that nitric oxide (NO) synthesis was 
responsible. IL-2 induced behavioral changes and vasodilation were attenuated in eNOS 
knockout mice, while permeability was abrogated in both eNOS and iNOS knockout 
mice. These results establish that activation of eNOS-mediated vasodilation and vascular 
permeability changes correlate with motor function changes induced by IL-2. NO does 
not appear to mediate early changes in spontaneous behavior. 
 
Introduction 
 At low concentrations (10–100 IU/ml), IL-2 is a cytokine that is essential for 
activation and clonal expansion of cytotoxic lymphocytes (1). Higher concentrations of 
IL-2 (> 600 IU/ml) result in activation of natural killer cell-derived cytotoxic 
lymphocytes called lymphokine-activated killer (LAK) cells (2). These cells kill tumor 
cells with antigen-independent mechanisms (3), and therefore demonstrate cytotoxicity 
against almost all freshly isolated (4) and cultured malignant cells (5), including 




established the anticancer activity of IL-2 (7-8). There has been a dramatic increase in 
treatment options for metastatic renal cancer and melanoma in the past 4 years, including 
development of “targeted” therapy such as mTOR (mammalian target of rapamycin) and 
VEGF (vascular endothelial growth factor) pathway inhibitors (9), as well as V600E B-
raf specific inhibitors (10). However, IL-2 remains the only therapy that can induce 
durable complete remissions in approximately 5–10% of patients with these cancers (11-
12). Clinical follow-up of these remissions in some cases now extends to over 20 years. 
Other currently available agents require lengthy administration of expensive drugs to 
maintain clinical responses, with eventual, but inevitable tumor progression and death. 
 Broader applications of IL-2 in cancer therapy are restricted by severe dose-
limiting toxicities (13-14). Two major cardiovascular toxicities of IL-2 administration are 
vascular leak syndrome (VLS) and hypotension. VLS is characterized by generalized 
extravasations of intravascular fluid into interstitial tissues, fluid retention (weight gain), 
noncardiac pulmonary edema, and reversible renal dysfunction (15). In conjunction with 
VLS and intravascular volume depletion, IL-2 also results in hypotension, due to 
decreased systemic vascular resistance. These toxicities result in hypoperfusion of vital 
organs, such as kidneys and heart (16). 
 IL-2 induced cardiovascular toxicities are thought to be indirectly mediated via a 
large number of secondarily released inflammatory cytokines, termed a “cytokine storm” 
(17). These cytokines include tumor necrosis factor (TNFα and TNFβ), IFN-γ, IL-1, IL-
5, and IL-6 (18-21). High doses of steroids can block IL-2 induced toxicity, but also 
completely abrogate therapeutic responses (22). These inflammatory mediators induce 




pathway (23-27). Hibbs et al. showed that serum and urine nitrate levels (metabolites of 
NO) are elevated 6- to 10-fold in patients on days 5–7 after a 5-day treatment course of 
IL-2 (28). Previous studies in our lab suggested that the mechanism of IL-2 induced VLS 
results from induction of NO synthesis (29), while hypotension appears to be due to 
catecholamine oxidation (30). 
 Our clinical experience with pharmacological inhibitors of hypotension and VLS 
suggests that dose escalation of IL-2 therapy is further limited by the onset of 
neuropsychiatric toxicity, even if other cardiovascular toxicity is controlled. A large 
percentage of patients develop some manifestations of neuropsychiatric toxicity while 
receiving IL-2 treatment, with 30–50% of patients experiencing cognitive and behavioral 
changes (31). Perhaps 10–20% of patients develop more severe manifestations, such as 
agitation, hallucinations, or delusions. To date, the pathophysiology of IL-2 induced 
neuropsychiatric toxicity is not well understood. We have therefore utilized IL-2 
treatment murine model to characterize cytokine-induced changes in the central nervous 
system (CNS) that lead to neuropsychiatric toxicity. 
 
Materials and Methods 
Mice. Pathogen-free C3H/HeN and C57/Bl6 mice were purchased from Charles 
River Laboratories. Breeding pairs of eNOS-/- mice (B6.129P2-Nos3tm1Unc/J) were 
purchased from Jackson Laboratories and bred by heterozygous male to homozygous 
eNOS-/- female mating. iNOS-/- mice backcrossed onto a C57/Bl6 background were 
generously donated by Dr. Victor Laubach (University of Virginia, Charlottesville, VA) 




previously described (32-33). WT C57/Bl6 served as controls for experiments with the 
knockout mice. Mice were maintained under guidelines established by the Institutional 
Animal Care and Use Committee (IACUC), which also approved all experimental 
protocols. Mice were age- and sex-matched in each experiment. Knockout mice were 
genotyped before being used in experiments. 
Verification of genotype of knockout mice. iNOS-/- mice were genotyped using 
previously published methods (29). eNOS-/- mice were genotyped using similar methods 
with the following primers: oIMR1823 – 5' ATT TCC TGT CCC CTG CCT TC 3' 
(common upstream primer), oIMR1824 – 5' GGC CAG TCT CAG AGC CAT AC 3' (lies 
in exon 12, which is deleted in mutant), and oIMR0094 – 5' TGG CTA CCC GTG ATA 
TTG CT 3' (neo cassette specific primer), and these changes in PCR parameters: 
annealing at 65oC and 35 cycles. eNOS-/- produced a 500 bp PCR product whereas WT 
yielded a 442 bp product and heterozygotes yielded both. 
IL-2 treatment. C3H/HeN mice were treated with 150,000 IU of IL-2 
(Proleukin®; Novartis, Emeryville, CA) intraperitoneally (i.p.), b.i.d. (twice a day) for 5 
days (a total of 10 doses) or 8 doses (4 days) for mice used in MRI studies to decrease 
anesthetic-induced mortality during scanning. C57/Bl6, eNOS-/-, and iNOS-/- mice were 
treated with 800,000 IU of IL-2 i.p., b.i.d. for 5 days (10 doses), as we have previously 
established this to be the equipotent dose to induce hypotension and VLS in this mouse 
strain (29). Initial dilutions of IL-2 were made in sterile water and further diluted in PBS 
(phosphate buffered saline) immediately prior to administration. Control mice received 




Measurement of spontaneous motor activity. Mouse spontaneous motor 
activity was measured using an Opto-Varimex apparatus (Columbus Instruments, 
Columbus, OH) as previously described (34). In a single experiment, 2 Opto-Varimex 
activity monitors (42.2 x 42.5 x 20.5 cm) were used. After the mice were acclimated to 
the environment of the activity monitors for 10 min, spontaneous activity was recorded 
for 60 min in an isolated room (dark and no noise) in the evening. The following 
parameters were analyzed using an Auto-Track software (Columbus Instruments, 
Columbus, OH): 1) total distance traveled by the animal in 1 hour (centimeters), 2) 
stereotypic activity count (grooming), and 3) vertical activity (rearing). Each mouse was 
acclimated to the apparatus prior to IL-2 treatment, serving as its own control. The post-
IL-2 data were then expressed as percentages of baseline (pre-IL-2) for each mouse and 
averaged for each day. 
 Motor coordination. Mouse motor coordination and balance were assessed using 
a 3-cm diameter rod rotating at a fixed speed of 20 revolutions per minute (rpm) (35). 
Normal mice can walk on the rotor rod without falling for 180 seconds (36-37). All mice 
were trained on the rotor rod daily for 7 days prior to the onset of IL-2 treatment. Each 
animal acted as its own control. Measurements were obtained every day during IL-2 
treatment. 
 Immunohistochemistry. Mice brains were processed and analyzed as previously 
described (38). Digital image size in pixel was converted to mm (17 pixels = 1 mm). 
 DCE MRI. DCE MRI of C3H/HeN mice was performed as previously described 
(38). C57/Bl6 WT, eNOS-/-, and iNOS-/- mice were scanned using the following T1-




ms, echo time (TE) of 3.06 ms, 40º flip angle, 1 mm slice thickness, number of slices = 
10, field of view = 2 x 2 cm, matrix = 128 x 128 pixels, a single scan time of 8.159 s, and 
60 total repetitions. Each mouse was scanned before and after IL-2 treatment, serving as 
its own control. Image analysis was performed as previously described (38). 
Statistical analysis. All data are expressed as mean±standard error of the mean 
(SEM). Statistics of the immunohistochemistry data were analyzed using 3-factor 
analysis of variance (ANOVA) including treatment group, mouse type, and brain region 
as sources of variation. The Auto-track data were analyzed as repeated measures using 
linear mixed models. Fixed factors included in the model were the baseline covariate, 
group (either mouse type or treatment group), time, and the group by time interaction. A 
random factor for mouse was included to account for within animal correlation. Between 
and within group comparisons were tested at the alpha = 0.05 significance level. MRI and 
rotor rod data were analyzed using paired Student’s 2-tailed t-test using GraphPad 
PRISM software (GraphPad Software, La Jolla, CA), unless otherwise indicated. A p-
value ≤ 0.05 was considered significant. 
 
Results 
IL-2 induced behavioral changes in mice. Changes in spontaneous behavior of 
mice were quantified following daily treatment with IL-2 (n = 3) using the Opto-Varimex 
apparatus and Auto-Track software (Columbus Instruments, Columbus, OH). 
Spontaneous mobility over 60 min was significantly decreased by 50% after only 4 doses 
of 150,000 IU IL-2 (day 2 measurement; p = 0.0005) and further decreased over 5 days of 




reduced by day 2 of IL-2 treatment. On day 2, control mice reared 125±16% baseline vs. 
IL-2 treated 49±16% baseline, p = 0.0041 (Fig. 3.1b). Grooming activities of control 
mice on day 2 were 106±12% baseline vs. IL-2 treated 64±12% baseline, p = 0.0218 
(Fig. 3.1c). Rearing and grooming activities of the IL-2 treated mice consistently 
decreased after day 2. These data establish that IL-2 induced substantial behavioral 
changes in mice. 
 To evaluate physical strength and coordination, mice were tested by rotor rod 
during IL-2 treatment (n = 5). The results showed that motor impairment in the mice did 
not occur until day 4 of IL-2 treatment. The ability of mice to balance on the rotor rod 
decreased to 18.6±3.5 seconds on day 4 and further decreased to 5.7±0.7 seconds on day 
5, compared to the normal mice (> 180 seconds), p < 0.0001 (Fig. 3.1d). These data 
suggest that changes in spontaneous behavior induced by IL-2 treatment occurred well 
before the onset of motor impairment, which was observed on day 4 or 5 when IL-2 
treated mice are known to be profoundly hypotensive (39). 
Vasodilation of brain blood vessels in IL-2 treated mice. NO derived from 
endothelial cells or pharmacologic donors induces peripheral vasodilation by causing 
relaxation of endothelial smooth muscle cells (40-42). Hibbs et al. have shown that IL-2 
treatment increases systemic NO production (28). We evaluated whether IL-2 induces 
vasodilation of brain blood vessels in IL-2 treated mice (n = 3) using 
immunohistochemistry. Frozen sections (6 µm) were carefully prepared from a defined 
anatomic region of the mouse mid-brain, as previously described (38). This region was 
chosen to reflect highly vascular areas based on a detailed mouse brain anatomy study by 








IL-2 induced behavioral changes in mice. Spontaneous nocturnal activity of C3H/HeN 
mice (n = 3) was measured using the Auto-Track system for 60 min each day. Mice were 
evaluated prior to treatment and daily during treatment with 150,000 IU IL-2 or same 
volume of PBS i.p., b.i.d. for 5 days. The post-IL-2 data were expressed as % of pre-IL-2 
(baseline) for each mouse and averaged for each day. In Panel (a) total distance travelled 
in 1h is shown on a daily basis. Panel (b) vertical activity/rearing and (c) stereotypical 
activity/grooming are also shown. In panel (d) a rotor rod study was used to evaluate 
physical strength and coordination of C3H/HeN mice (n = 5) prior to and during IL-2 
treatment. Results are expressed as mean±SEM. The p-values for between group 


























    
 






vascular pericytes and antibody to von Willebrand Factor (anti-vWF) to identify 
endothelial cells. Staining was evaluated in twenty 20x magnification digital images of 
the areas selected, which include the cortex, the cerebral fissure, and the striatum. Each 
image was analyzed for the numbers and average size of dual-stained blood vessels. The 
results showed that the average size of vessels in the brain of IL-2 treated mice (131±19 
mm2) was almost 2-fold more dilated than in control mice (71±19 mm2), p = 0.0389 (Fig. 
3.2a), while the number of vessels in the brain were not significantly different between 
the IL-2 treated (8±2) and control mice (7±2), p = 0.7765 (Fig. 3.2b). These results 
suggest that IL-2 induces substantial vasodilation of the brain blood vessels. 
Effects of IL-2 on brain microvasculature permeability. We evaluated possible 
IL-2 induced changes in the mouse brain microvasculature permeability using dynamic 
contrast enhanced (DCE) MRI (magnetic resonance imaging). This technique has been 
used to assess tumor vascular permeability in patients and animal models (44-45). We 
developed a protocol to evaluate the brain microvasculature of IL-2 treated mice by DCE 
MRI (38). This technique was used to quantify 3 vascular parameters: 1) fractional 
plasma volume (fPV) describes the plasma volume of the blood vessels in the tissue 
(mouse brain), 2) endothelium transfer coefficient (KPS) reflects the permeability of the 
contrast agent from the blood vessels to the extravascular and extracellular space (EES) 
of the tissue, and 3) permeability surface area product (PS), which is the product of fPV 
and KPS, describes the permeability of the vasculature in the tissue to the contrast agent 
(46-47). Our experimental results demonstrated a 2-fold increase of fPV in the mice brain 
(n = 5) after receiving IL-2 treatment for 4 days (0.016±0.002 pre-IL-2 vs. 0.031±0.006 








Vasodilation of brain blood vessels in IL-2 treated mice. C3H/HeN mice were treated 
with IL-2 (150,000 U i.p., b.i.d. for 5 days). Immediately following completion of IL-2 
treatment, mice were sacrificed and the brains excised. The brain was embedded and 
frozen. Frozen sections (6 µm) were prepared and blood vessels were identified by dual-
staining with Iso-B4 and anti-vWF. ImageJ software was used to analyze the area and 
numbers of blood vessels that were manually outlined on digitized fluorescence images 
of 4 different areas in the left and right cortex, left and right striatum, and the cerebral 
fissure (20 regions of interest/n). In panel (a) representative images of a specific area of 
the brain section. Arrow indicates a dual-stained blood vessel. (b) IL-2 treatment 
significantly increased the average area of blood vessels in matched 6 µm-thick mid-
brain sections from IL-2 treated and control mice (n = 3). (c) The number of blood 
vessels in the brain was not significantly changed by IL-2. Results are expressed as 
















permeability (KPS) to the contrast agent was also seen following IL-2 treatment 
(0.204±0.039 ml/min/100 cm3 pre-IL-2 vs. 0.431±0.052 ml/min/100 cm3 following IL-2 
treatment), p = 0.0079 (Fig. 3.3b). Finally, the PS was 0.003±0.0005 ml/min/100 cm3 in 
the mice prior to the IL-2 treatment and increased to 0.013±0.0022 ml/min/100 cm3 after 
receiving IL-2 (Fig. 3.3c). These data suggested a 2-fold increase in the plasma volume 
and permeability of the brain blood vessels, which yielded a 4-fold increase in the blood 
vessel surface area in the mouse brain that became “leaky” to the contrast agent after IL-2 
treatment (p = 0.0083). 
Roles of NO in IL-2 induced CNS effects. Our previous laboratory data suggest 
that NO production derived from eNOS, rather than iNOS, contributes to IL-2 induced 
systemic VLS (29 and manuscript submitted). We therefore utilized eNOS knockout 
(eNOS-/-) mice to determine the role of eNOS-derived NO in IL-2 induced neurotoxicity, 
by evaluating vasodilation and microvascular permeability in the brain. 
Immunohistochemistry of eNOS-/- brain blood vessels (n = 3, 20 digital images/n) using 
Iso-B4 and anti-vWF dual staining (as previously described (38)) showed that eNOS-/- 
developed only an attenuated and statistically insignificant vasodilation in the brain 
following IL-2 treatment (average vessel size of 42±19 mm2 vs. control 27±19 mm2), p = 
0.5827 (Fig. 3.4a). DCE MRI data further showed that the fPV value in eNOS-/- mice did 
not significantly increase following IL-2 treatment (p = 0.173) as it did in wild-type (WT) 
and iNOS-/- mice (p < 0.001 and 0.029, respectively; Fig. 3.4b). Similar to C3H/HeN 
mice, IL-2 treatment also increased KPS and PS values in WT C57/Bl6 mice (Fig. 3.4c 
and 3.4d). Surprisingly, IL-2 treatment induced negative changes in KPS and PS values 








Effects of IL-2 on brain plasma volume and microvascular permeability in mice 
evaluated by DCE MRI. C3H/HeN mice (n = 5) were scanned with a 7T MRI scanner 
using a T1-weighted 2D-FLASH MRI sequence before and after 4 days of IL-2 treatment 
(150,000 U i.p., b.i.d.). Signal intensity from a manually drawn ROI on a selected 1-mm 
mid brain section of each mouse was calculated using customized MATLAB programs. 
The contrast agent concentration in the blood pool was derived by averaging the signal 
intensities of the left and right maxillary veins. A two-compartment model was used to 
calculate the vascular parameters. In panel (a) IL-2 increased the fractional plasma 
volume (fPV) in the brain by 2-fold. (b) IL-2 increased the permeability of contrast agent 
from the blood vessels to the brain EES (KPS) by 2-fold. (c) The surface of the brain 
blood vessels that becomes permeable to the contrast agent (PS) increased by 4-fold after 








         








IL-2 induced vasodilation and microvascular permeability in the brain are abrogated in 
eNOS-/- mice. (a) Brain blood vessels immunohistochemistry of eNOS-/- mice did not 
show vasodilation following IL-2 treatment (800,000 U i.p., b.i.d. for 5 days). Matched 6-
µm frozen mid-brain sections of IL-2 treated and control eNOS-/- mice (n = 3) were dual-
stained with Iso-B4 and anti-vWF to identify blood vessels. ImageJ software was used to 
analyze the area of blood vessels that were manually outlined on digitized fluorescence 
images of 4 different areas in the left and right cortex, left and right striatum, and the 
cerebral fissure (20 regions of interest/n). (b, c, d) eNOS-/- mice do not show positive 
cerebrovascular changes following IL-2 treatment evaluated using DCE MRI. The fPV, 
KPS, and PS values of WT C57/Bl6, eNOS-/-, and iNOS-/- mice (n = 4) were obtained as 
previously described before and after 5 days of IL-2 treatment (800,000U i.p., b.i.d.) and 
the values following IL-2 treatment were subtracted with the values prior to IL-2 
treatment for each mouse. The differences (∆fPV, ∆KPS, and ∆PS) were then analyzed 
using analysis of variance (ANOVA) techniques. A single-factor ANOVA using the 
mouse type (WT, eNOS-/-, and iNOS-/-) as the source of variation was conducted. 
Comparisons between groups were tested at the alpha = 0.05 significance level using 
Turkey’s multiple comparisons method. Within each group changes were tested for each 








                     
     











     
 






only ∆KPS of iNOS-/- mice showed significance (p = 0.04). Both ∆KPS and ∆PS of eNOS-/- 
and iNOS-/- mice are statistically different compared to the WT mice. These data indicate 
that eNOS-derived NO plays a major role in IL-2 induced vasodilation and microvascular 
permeability in the brain, while iNOS-derived NO may also contribute to brain 
microvascular permeability but not vasodilation. 
 Unexpectedly, there were no significant differences in behavior changes between 
WT, eNOS-/-, and iNOS-/- mice (n = 4). All mice showed decreased spontaneous mobility 
over 60 min (Fig. 3.5a), rearing (Fig. 3.5b), and grooming (Fig. 3.5c) following IL-2 
treatment. However, when we compared the post-IL-2 vs. pre-IL-2 (averaged over 4 days 
prior to the onset of IL-2 treatment as day 0 value = 100%) data within each group, the 
results showed that the spontaneous behaviors of WT and iNOS-/- mice were significantly 
reduced by day 3 of IL-2 treatment whereas the eNOS-/- mice did not show significant 
decreases in all 3 activities measured until day 4. Furthermore, WT and eNOS-/- mice 
were able to stay on the rotor rod for 180 seconds for the whole period of IL-2 
administration, while 2 out of 4 iNOS-/- mice could not complete this test by day 5, p = 
0.089 (Fig. 3.5d), and eventually died of IL-2 toxicity on day 6. There was no IL-2 
induced mortality in eNOS knockout mice. These data suggest that IL-2 induced 




 In mice, the therapeutic effectiveness is closely related to the dose of the drug 








IL-2 induced behavioral changes were attenuated in eNOS-/- mice. Spontaneous nocturnal 
activities of WT C57/Bl6, eNOS-/-, and iNOS-/- mice (n = 4) were measured using the 
Auto-Track system (as previously described) prior to and daily during treatment with 
800,000 IU IL-2 i.p., b.i.d. for 5 days and expressed as % of baseline. In Panel (a) total 
distance travelled in 1h is shown on a daily basis. Panel (b) vertical activity/rearing and 
(c) stereotypical activity/grooming are also shown. In Panel (d) a rotor rod study was 
used to evaluate physical strength and coordination prior to and during IL-2 treatment of 








      
 









    
 






higher response and complete response rate than intermediate dose or low dose IL-2 (49). 
The effectiveness of IL-2 therapy as a human cancer treatment is, however, markedly 
limited by cardiovascular and neuropsychiatric toxicities (13-14, 31). While the 
cardiovascular toxicities can be managed with pressor agents and fluid administration, the 
neuropsychiatric toxicity is the least predictable and controllable. This toxicity invariably 
leads to treatment discontinuation. Approximately 10–20% of patients receiving IL-2 
therapy become agitated, sometimes with delusions or hallucinations, and at least 30–
50% have more subtle CNS changes, such as mental slowing or confusion. The 
pathophysiology of this toxicity remains poorly understood. 
 Studies attempted to delineate IL-2-induced neuropsychiatric toxicity have been 
limited by the availability of suitable experimental techniques, as well as the technical 
challenges of performing DCE MRI studies in critically ill patients. A previous study 
looking at the effects of IL-2 in the brain of patients with extracranial cancer without 
evidence of intracranial metastases using T2-weighted MRI suggested a massive increase 
of cerebral water content in both the gray matter (12.6±7.3%) and white matter 
(17±6.2%) after IL-2 therapy (50). However, only 3 out of these 7 patients were mildly 
lethargic, and the range of these measurements varied from 3–48%, raising questions 
concerning the accuracy of these results. The magnitudes of these apparent cerebral water 
content increases are also difficult to believe as they are far greater than the magnitude of 
VLS measured in any other organ or even compared to the overall weight changes in the 
intact IL-2 treated animals or patients (approximately 6–8%). Studies in cats and rats 
have shown that a single intravenous injection of recombinant IL-2 increased the 




blood-brain barrier (BBB) and cerebrovascular morphological integrity (51-52). Another 
study on the effect of IL-2 on the CNS in rat gliosarcoma model suggested that IL-2 
increased the transfer constant of carbon-14-labeled aminoisobutyric acid from the BBB 
into the brain of tumor-bearing rat brains, but not in normal brains (53). The significance 
of this finding is uncertain, since brain tumors are known to have abnormal blood vessel 
permeability and consequently could have contributed to the increased brain edema 
following IL-2 treatment. We therefore evaluated behavioral and CNS changes induced 
by IL-2 treatment in the normal brain using a well-characterized murine model (30, 54). 
 In the current study, behavioral changes were observed as early as day 2 
following the onset of IL-2 treatment (Fig. 3.1a–c), well before the onset of motor 
impairment. Motor impairment occurred on day 4 of IL-2 treatment (Fig. 3.1d), when the 
mice are known to be profoundly hypotensive (39). These results indicate that the 
decreases in the spontaneous behavior of these mice were not due to the mice being too 
sick to move. Instead, these data suggest that IL-2 affects the CNS in a manner distinct 
from the dose-limiting systemic cardiovascular effects of IL-2. 
 We have evaluated a number of approaches to assess cerebrovascular changes in 
IL-2 treated mice (38). We analyzed vascular regions of the mid-brain section, which 
includes the striatum and cerebral cortex. Both of these brain regions are within the gray 
matter, consisting of the glial cells (astroglia and oligodendrocyte), neuronal cell bodies, 
neuropil (dendrites and axons), and capillary blood vessels. We also assessed the regions 
of interest in the striatum, which is best known for its role in cognitive processes, and the 
cerebral cortex, which plays an essential role in attention, memory, thought, perceptual 




induced vasodilation of the blood vessels in these regions (Fig. 3.2). This was confirmed 
by DCE MRI, which showed both vasodilation and increased permeability of blood 
vessels in these specific anatomic regions in mice that appeared to correlate with 
behavioral changes (Fig. 3.3). 
 NO has been shown to mediate IL-2-induced VLS (55), presumably via 
alterations of the tight junctions between endothelial cells. Our previous studies in iNOS-
/-
 and eNOS-/- mice have further demonstrated that NO production via the eNOS isoform, 
rather than the iNOS isoform, in the systemic circulation is necessary for VLS (29 and 
manuscript submitted). The role of NO in the IL-2-induced CNS effects has not 
previously been evaluated. Since we showed that IL-2 induces vasodilation of the brain 
blood vessels, we evaluated whether eNOS- or iNOS-derived NO contributes to IL-2 
induced neurologic changes. Our current results show that eNOS-/- mice exhibited 
decreased vasodilation and microvascular permeability following IL-2 treatment (Fig. 
3.4), indicating a key role of this enzyme in IL-2 induced brain microvasculature 
changes. On the other hand, iNOS-derived NO seems to contribute to IL-2 induced 
microvascular permeability in the brain (Fig. 3.4c–d). Further analyses of these DCE 
MRI data indicate that eNOS-/- and iNOS-/- mice develop leaky brain blood vessels prior 
to IL-2 treatment, and this permeability is decreased following IL-2 treatment (Fig. 3.4c–
d). This phenomenon is very intriguing. These knockout mice develop normally and it is 
not previously known that they have leaky blood vessels. Although they seem to be more 
aggressive than the WT mice, their behavioral studies prior to IL-2 show similar data as 
the WT mice (Fig. 3.5). One possible explanation is that IL-2 synthesis strongly induces 




mice without NO production (due to knockout of eNOS or iNOS), the compensatory 
pathway may still be strongly induced, decreasing microvascular permeability in the 
brain. The mechanisms that appear to decrease vascular permeability in eNOS-/- or iNOS-
/-
 mice will require further investigation. 
 Unexpectedly, eNOS-/- mice still showed measurable behavioral changes 
following IL-2 treatment (Fig. 3.5a–c) although these changes were attenuated compared 
to the WT and iNOS-/- mice. We considered that NO produced by the iNOS isoform 
might contribute to some of these behavioral changes. This possibility appears unlikely as 
administration of L-N6-(1-Imminoethyl)lysine (L-NIL, a relatively specific inhibitor of 
iNOS (56)) to eNOS-/- mice failed to prevent IL-2 induced behavioral changes (data not 
shown). These results suggest that there may be additional mechanisms involved in IL-2-
induced neurologic changes in mice. This may be similar to the observations in thiamine-
deficient mice, where the eNOS gene knockout prevented blood brain barrier disruption 
but not neuronal cell loss (57).  It should also be noted that our DCE MRI data on 
C3H/HeN mice indicated no significant changes in fPV, KPS, and PS values on day 3 of 
IL-2 treatment (data not shown), whereas the behavioral changes were observed as early 
as day 2. These data suggest that IL-2 induced behavior and cognitive changes occurred 
before detectable IL-2 induced vasodilation and microvascular permeability. We 
therefore hypothesize that other mechanisms, such as the release of excitatory 
neurotransmitters, may contribute to the changes in behavior and cognitive functions 
observed at early time points during IL-2 treatment while the eNOS-mediated 
vasodilation and microvascular permeability in the CNS contribute to neuropsychiatric 




 It should be noted that there are striking similarities in the pattern of IL-2 induced 
VLS, hypotension, and delirium (neuropsychiatric toxicity) with the initial phase of 
septic shock (16). This is also associated with the rapid onset of a similar “cytokine 
storm” and pathophysiologic features (58-60). Sepsis progresses rapidly (in hours) to a 
refractory shock, associated with organ failure and a high mortality rate. IL-2 treatment 
may be a convenient model to study the cardiovascular and neurologic mechanisms 
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 Despite other currently available chemotherapy for metastatic melanoma and 
renal cell carcinoma (1-2), IL-2 is the only agent that can induce durable complete 
remissions in approximately 5-10% of patients with these cancers (3-4). Unfortunately, 
IL-2-induced cardiovascular and neuropsychiatric toxicities (5-7) limit the administration 
of high dose IL-2 required to achieve complete remissions. While the cardiovascular 
toxicities can be attenuated in patients by administration of pressor agents and fluid, the 
neuropsychiatric toxicity can only be managed by holding further doses of IL-2. Studies 
using a nonpeptidyl mimic of O2- dismutase, NOS inhibitors, and NOS knockout mice 
have shed some light on the mechanisms involved in IL-2-induced hypotension and VLS 
(8-10). On the other hand, the pathophysiology of IL-2-induced neuropsychiatric toxicity 
was previously unclear. 
 Previous studies attempting to look at the effects of IL-2 in the CNS have 
suggested an increase in BBB permeability and therefore brain edema (11-14). However, 
some of these results are questionable. Further attempts to delineate IL-2-induced 
neuropsychiatric toxicity have been limited mostly by the availability of suitable 
experimental techniques. Therefore, we first evaluated and developed a number of 
potential experimental methods that could quantify cerebrovascular changes in an 
established murine IL-2 treatment model (8, 15). Our evaluations showed that assays 
quantifying changes in the mouse brain interstitial fluid following IL-2 treatment (i.e. wet 
versus dry brain weight, MRI proton density measurement, and quantification of 
radioactive labeled [125I]-bovine serum albumin, tritiated water, or fluorescence marker), 
were not informative due to lack of sensitivity to accurately measure the small changes in 
the mouse brain water content. Two successful methods identified include DCE MRI and 
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quantitative analysis of the mouse brain blood vessels dual-stained with isolectin GS-IB4 
and an antibody to von Willebrand factor. The data demonstrated that IL-2 induced 
vasodilation and microvascular permeability in the mid-brain section containing the 
cerebral cortex and striatum, which correlate with cognitive and behavioral changes. 
 Previous data in our lab have shown that by day 4 and 5 following IL-2 treatment, 
IL-2 treated mice have a blood pressure of < 40 mmHg (16) and a significantly decreased 
serum albumin (unpublished), resulting in low hydrostatic and osmotic pressures within 
the vasculature. Thus, the increase of contrast agent in the IL-2 treated mouse brain 
detected by DCE MRI is not likely due to a hydrostatic pressure-induced filtration, as 
decreased systolic pressure should decrease these forces. In the presence of decreased 
hydrostatic pressure, the only way to fully account for the identified changes is an 
increase in BBB permeability acting in concert with decreased osmotic forces. As the 
contrast agent was injected gently by hand during all DCE MRI procedures through a thin 
bore tube that is not amenable to high injection pressures, artifact changes seem unlikely. 
A high-pressure automatic injector device (pump), such as usually used in patients, was 
not used. 
 Using a behavior monitoring system, we established that IL-2 treated mice 
exhibited behavioral changes, suggesting that IL-2 affects the CNS in a similar fashion in 
the murine model as in IL-2 treated patients. The behavioral changes in C3H/HeN mice 
were observed as early as day 2 (after 4 doses of 180,000 IU IL-2 i.p., b.i.d) following 
IL-2 treatment. This occurred long before the onset of severe motor impairment observed 
on day 4 when IL-2 treated mice are known to be profoundly hypotensive (16). These 
data indicate that decreases in the spontaneous behavior of these mice are not due to the 
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mice being too sick to move and that IL-2 affects the CNS via a different time course 
than the systemic cardiovascular toxicities of IL-2. 
 As NO derived from endothelial cells or pharmacologic donors is known to 
induce peripheral vasodilation and is thought to contribute to vascular permeability 
changes (17-19), we evaluated its role in the IL-2-induced vasodilation and microvascular 
permeability in the CNS using the immunohistochemistry and DCE MRI techniques. The 
results of these experiments established that IL-2-induced vasodilation and microvascular 
permeability were abrogated in eNOS-/- mice, demonstrating a causal role of this enzyme 
in IL-2-induced brain vasculature changes. These data are consistent with the crucial role 
of eNOS in IL-2-induced systemic cardiovascular toxicities (10). Interestingly, iNOS-/- 
mice still developed vasodilation following IL-2 treatment, but not microvascular 
permeability, suggesting that iNOS also plays a role in IL-2 induced microvascular 
permeability in the brain. 
 IL-2 is unique as it induces a transient autocrine feedback loop in T and NK 
lymphocytes, further increasing IL-2 synthesis. This result in a marked induction of a 
‘cytokine storm’ (20), which is thought to mediate IL-2-induced dose-limiting toxicities. 
However, questions remain whether IL-2 induces effects on the vasculature by binding 
directly onto IL-2 receptor (IL-2R) on the endothelial cells or indirectly via IL-2R on the 
leukocytes. There are several studies that suggest low level expression of IL-2R on 
endothelial cells. The functional relevance is currently poorly understood. We have 
performed preliminary experiments employing mice with homologous recombination in 
the IL-2Rα (CD25-/-). These mice are resistant to induction of IL-2 induced hypotension 







Assessment of whether IL-2 induces hypotension via IL-2 receptor (IL-2R) expression on 
endothelial cells or leukocytes. C57/Bl6 WT and IL-2Rα-/- mice (back-crossed onto a 
C57/Bl6 background, not 100% chimeras) were treated with 1 mg Ciprofloxacin i.p. once 
a day for 2 days followed by 25 mg/kg Busulfan i.p. once a day for 6 days to ablate 
endogenous bone marrow. Ciprofloxacin (0.18 mg/ml) was also added into the drinking 
water during the duration of the experiment. Two days after the last dose of Busulfan, 
2x106 syngeneic bone marrow cells were transferred into each mouse i.v. via the tail vein. 
Mice were allowed to reconstitute normal bone marrow function for 1 month. At this 
time, the hemato-immune cells in transplant recipient were predominantly of bone 
marrow donor origin, while the endothelium was of host derivation. C57/Bl6 WT, IL-
2Rα-/-, WT mice transplanted with bone marrow (BM) from either WT (WT/WTBM) or 
IL-2Rα-/- mice (WT/KOBM), and IL-2Rα-/- mice transplanted with WT bone marrow 
(KO/WTBM) (n = 3) were treated with 800,000 IU IL-2 i.p., b.i.d. for 5 days. On day 5, 
the blood pressure of each mouse was measured via tail cuff method (Stoelting, Wood 
Dell, IL) using PowerLab digital signal transducer (AD instruments, Mountain View, 
CA). Pulse and blood pressures were recorded onto a computer and analyzed using Chart 
3.6.1 software (AD instruments) to obtain systolic blood pressure of each mouse. Results 
are expressed as mean±SEM. The statistics were analyzed using 2-sample Student’s 2-
tailed t-test. A p-value ≤ 0.05 was considered significant and is indicated on the graph. 
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storm or in endothelial responsiveness. We therefore performed a transplant experiment 
to create chimeric mice. The results suggest that the presence of IL-2Rα on the immune 
cells, but not endothelial cells, is essential for IL-2-induced hypotension in mice (Fig. 
4.1). 
 Surprisingly, eNOS-/- mice still exhibited substantial behavioral changes 
following IL-2 treatment although these changes were attenuated compared to the WT 
and iNOS-/- mice. Administration of LNIL, a specific inhibitor of iNOS (21), to eNOS-/- 
failed to prevent IL-2-induced behavioral changes, indicating an additional mechanisms 
are likely to be involved in IL-2-induced neuropsychiatric changes. Furthermore, our 
DCE MRI data showed no significant changes in fPV, KPS, and PS values in C3H/HeN 
mice on day 3 of IL-2 treatment (Fig. 4.2), whereas the behavioral changes were 
observed as early as day 2 in these mice. These data suggest that IL-2-induced behavior 
and cognitive changes occurred before detectable IL-2 induced vasodilation and 
microvascular permeability. We hypothesize that excitatory neurotransmitters may also 
be increased in the brain following IL-2 treatment and may contribute to the 
neuropsychiatric toxicity observed at early time points during IL-2 treatment while the 
eNOS-mediated vasodilation and microvascular permeability in the CNS are likely to 
exacerbate this toxicity by days 4 and 5. The excitatory neurotransmitters may account 
for the frequent agitation, hallucinations, and delusions seen in human IL-2 treated 
patients. This possibility will require further investigation. 
 Collectively, this study provides the tools to evaluate other situations that result in 
cytokine-induced neuropsychiatric toxicity, i.e., sepsis or therapy with other 







DCE MRI following 3 days of IL-2 treatment (6 doses of 150,000 IU i.p., b.i.d.) to 
evaluate early changes in vasodilation and microvascular permeability induced by IL-2 in 
the brain. C3H/HeN mice (n = 5) were scanned both before and after 3 days of IL-2 
treatment using T1-weighted 2D-FLASH MRI sequence (TE/TR = 3.06 ms/84.992 ms, 
flip angle = 40º, slice thickness = 1 mm, number of slices = 10, field of view = 2 x 2 cm, 
matrix = 128 x 128 pixels, a single scan time = 8.159 s, number of repetitions = 60). 
After baseline imaging, 0.1 mmol/kg of gadobenate dimeglumine (MultiHance®, Bracco) 
was administered by bolus injection via tail vein catheterization. Customized MATLAB 
programs were used to measure signal intensities from manually drawn ROI on a selected 
1-mm mid-brain section of each mouse. The left and right maxillary veins were averaged 
to derive the contrast agent concentration in the blood pool and a two-compartment 
model was used to calculate A) fractional plasma volume (fPV), B) endothelium transfer 
coefficient (KPS), and C) permeability surface area product (PS). Results are expressed as 
mean±SEM. Statistical analysis was performed using paired Student’s 2-tailed t-test 



























































pathways upstream or downstream of eNOS that contribute to IL-2-induced vasodilation 
and microvascular permeability in the CNS is also feasible using these experimental 
methods. A longer-term goal of this line of investigation is to develop a more complete 
understanding of the mechanisms involved in IL-2-induced neuropsychiatric toxicity. 
This will be important to allow identification of pharmacologic inhibitors that block this 
toxicity in patients. Blockade of IL-2 induced cardiovascular and neurologic toxicities 
may enable dose escalation of IL-2 in human patients and may allow more patients to 
achieve complete and long-term remissions of otherwise incurable cancers. 
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